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Abstract

Peptides and peptide analogs are central to the understanding of biological and
biochemical phenomena as well as in the development of new pharmaceutical agents.
This research encompasses two classes of peptide mimetics: phosphonopeptides and
short, amphipathic peptides rich in oc,a-disubstituted amino acids (aaAA). The focus of
the first part of the peptide analog project was on the preparation of sterically-hindered
phosphonamide and thiophosphonamide dipeptides. Conditions were developed, based
on our P(m) synthetic approach, for the preparation of the phosphonamide dipeptides,
Cbz-CyhGly y [P (O) (OpNb) NH] Trp-NH2 and Cbz-CyhGly y [P (O) (OpNb) NH]
Trp-OMe, which were previously unattainable by P(V) methods. The use of reduced
phosphorus intermediates also allowed preparation of the related thiophosphonamides,
Cbz-CyhGly \|f [P (S) (OpNb) NH] Trp-NH2 and Cbz-CyhGly \|f [P (S) (OpNb) NH] TrpOMe.

With the P(IH) synthetic strategy we started from an amine-protected H-

phosphinate amino acid ester and activated, in the presence of 2 equivalents of pyridine,
with dichlorotriphenylphosphorane to generate a phosphonochloridite, which was treated
with a diisopropylethylamine to form a proposed, very reactive, oxazaphospholine. The
oxazaphospholine was coupled to an amine nucleophile followed by oxidation or
sulfurization. This method was also used to prepare several simpler phosphonamide and
thiophosphonamide dipeptides and thiophosphonates.
In the second part of this project a homologous series of 9-mer, aaAA-rich
peptides (and their acetylated versions), which were designed to be amphipathic and 310 helical, were prepared using solid-phase synthetic techniques.

The peptides were

composed of 78% aaAAs (one 4-aminopiperidine-4-carboxylic acid (Api) and six

xviii
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aminoisobutyric acid (Aib)). The in situ coupling agent, PyAOP, was used in the
synthesis. The use of Fmoc-Aib-Aib-OH in the syntheses caused a significant
improvement in the coupling and overall yields of the peptides. However, the monomer
Aib had to be incorporated, along with double coupling, for the first two Aibs in each
peptide’s sequence.
The helix preference of each peptide in different solvent environments were
investigated as well as each peptide’s antimicrobial activity and cytotoxicity. Significant
populations of both a- and 3to-helices were observed for the non-acetylated peptides
under the solvent conditions tested. The 3to-helical, amphipathic design was observed
best for the acetylated peptides. Most of the peptides exhibited modest activity against E.
coli and no activity against 5. aureus. The non-acetylated peptides (concentrations < 100
pM) and the acetylated peptides (concentrations < 200 pM) did not exhibit, based on a
trypan blue stain procedure, any significant cytotoxicity to normal macrophages.

xix
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Chapter 1
Introduction
1.1 A Brief Overview of Peptides and Peptide Analogs
Peptides, which are relatively low-molecular weight polymers of amino acids (in
contrast to high-molecular weight proteins), are present in most life forms. The amino
acids are linked together by a covalent peptide bond between the carboxyl end of one
amino acid and the a-amino end of another. Peptides play a key role in a diverse range of
biological processes.

Some examples of peptides found in the human body are

enkephalins, bradykinin, vasopressin, oxytocin, and glutathione.

Enkephalins are

pentapeptides whose primary function is pain control; they lessen pain sensitivity by
binding to receptors in certain brain cells. 1' 1' 1'2 Bradykinin, vasopressin, and oxytocin are
peptide (nonapeptides) hormones that inhibit tissue inflammation, control blood pressure,
and induce labor in pregnant women, respectively. 1’1 Glutathione is a tripeptide that
destroys harmful oxidizing agents in the body. 1' 1,1'3
Unfortunately, peptides and proteins also play a pivotal role in many chronic and
infectious diseases. 1'4' 18 Insulin-dependent diabetes is a disease that is believed to be
caused by otherwise innocent viral peptides. 14 They mimic peptides found in the human
body and stimulate the immune system to attack these self-peptides. 14-15 Rheumatoid
arthritis16 and multiple sclerosis1'7 are other autoimmune diseases where self-peptides are
erroneously seen as foreign species. Furthermore, the aberrant functioning of proteases,
which are an important class of enzymes that play key roles in a wide variety of
biological processes, often lead to physical and mental ailments. 1 8

1

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2

Molecular recognition of a peptide by a macromolecular receptor is crucial to the
processes or disorders mentioned above. 14*1'9 Therefore, peptides themselves seem to be
the first obvious candidates to interfere with this action.
advantageous to use peptides in drug therapy.

However, it is often not

In general, peptides have poor

pharmacokinetic properties that limit their use as drugs. If given orally, they are prone to
degradation by proteases in the stomach as well as poor absorption in the intestinal
system. 1' 10 Even if peptides are given intravenously, their activity is often short-lived
because proteolytic enzymes in the blood and in other tissues rapidly degrade them. 111
The disadvantages of peptide drugs have stimulated an intense quest for peptide
analogs. 1' 12*1 15
A peptide analog or a peptidomimetic is a compound that mimics the critical
features (e.g., shape and functionality) of a parent peptide. 1' 16*117 Peptidomimetics are
often designed to be more stable and sometimes more active than peptides. For example,
increased proteolytic stability can be achieved by replacing the amide bond by alkene
bonds (as seen in a vinylogous peptide) 1 18 or placing the amino acid side-chain on the
nitrogen atom (as seen in a peptoid) . 1 19 It is also desirable for peptide analogs to have
high-yielding coupling steps that are amenable to automation, which could lead to faster
exploration of the space of chemical diversity for compounds with the desired
properties. 1' 11' 1' 12 Presented in Figure 1.1 are examples of several classes of peptide
analogs; phosphonopeptides and a,a-dialkylated peptides are the foci of this dissertation.
The general design of both of these peptide mimetics also allows for increased proteolytic
stability as well as some bioactivity.
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1.2 Importance of Phosphonopeptides
Phosphonopeptides (organophosphorus V derivatives) are a significant, stable
class of biologically active peptide mimics. 12(M'21 In phosphonopeptides, as seen in
Figure 1.1, the scissile peptide linkage is replaced with a tetrahedral phosphorus ester or
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Figure 1.1 Gasses of peptide analogs
amide moiety group. They emulate high-energy tetrahedral transition states that are
common to many enzyme-catalyzed pepdde hydrolysis reactions; hence, they are useful
in the elucidation of enzyme mechanisms and as enzyme inhibitors. 1^ 2 Such transitionstate analogs have been employed as effective inhibitors of serine (e.g., chymotrypsin and
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human leukocyte elastase) , 123' 124 metallo (e.g., carboxypeptidase A and angiotensinconverting enzyme) , 1'25' 1'26 and aspartyl (e.g., pencillopepsin and HIV proteases) , l1 5 ,127
proteases (Figure 1.2). Scheme 1.1 is an example of a metallo-protease catalyzing the
hydrolysis of an amide bond in a model peptide or protein; the high-energy tetrahedral
intermediate is bound more tightly than the substrate. 1.28-1.29

The inhibition of the

metallo-protease by a model phosphonopeptide is also shown in Scheme 1.1; good
potential inhibitors of the enzyme will bind more tightly than the substrates. 139
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Figure 12 Phosphonopeptide enzyme inhibitors
Several phosphonopeptides have also shown powerful antibacterial activity. 1"30"132
Allen et al. reported the design and synthesis of the first phosphono-based antibacterial
agent, alafosfalin. 130 Several phosphonopeptide derivatives, based on alafosfalin, have
since been reported. 132 They have been shown to have activity against several bacterial
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species such as Escherichia coli, Staphylococcus aureus, Bacillus subtilis, and Serratia
marcescens. 132
More recently, phosphonopeptides have been applied to hapten design for
generation of catalytic antibodies that possess peptide ligase activity. 133 It is possible to
generate antibodies with enzymatic activity by choosing haptens that are analogous to the
transition state of the substrate for a chemical reaction. 1'33*134 When a transition-state
analogue is employed as a hapten, it induces an array of different antibodies that bind the
hapten specifically. 1'34 Hirschmann et al. reported the antibody-catalyzed formation of a
dipeptide; a phosphonate diester hapten was employed (Scheme 1.2) . 133
Zinc protease m echanism
R’NH

R’NH
Glu -C 61

^i-O H

tetrahedral intermediate

Zinc protease inhibition

Glu-C.

Glu-C

Scheme 1.1 Enzyme-catalyzed peptide hydrolysis (top) and enzyme inhibition (bottom)

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

6

T
‘NH
O

R

Catalytic
Antibody

H2N

O

O2N

H O, ,,0
r

O

R H H o

O

O

o

'

r

NHz

O

Proposed intermediate
Hapten used to generate catalytic antibody

Scheme 1.2 Peptide synthesis catalyzed by an antibody
13 Synthetic Strategies for Phosphonate Esters and Amides
Generally, phosphonate and phosphonamide peptide analogs are prepared by
coupling a phosphonochloridate (P (V) compound) with an alcohol or amine nucleophile,
respectively (Scheme 1.3). Phosphonochloridates, for this purpose, have been obtained
by the reaction of phosphonate diesters with phosphorus pentachloride, 135 ‘ 137 by the
treatment of phosphonate monoesters with thionyl chloride or oxalyl chloride, 115,128,138
and by oxidative activation of H-phosphinate esters with carbon tetrachloride. 1 39 These
reactions, phosphonochloridates with alcohol or amine nucleophiles, are usually sluggish
and low to moderate yielding, which are due, to some extent, to the slow nucleophilic
attack on the phosphorus (V) center. 140 Moreover, for the amine nucleophiles, the
amount of HC1 that is produced in the reaction mixtures often interferes with the desired
coupling process, even if excess base (e.g., EtjN) is employed. 139
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Scheme 13 Preparation of a phosphonopeptide via an activated P(V) species
Improved synthetic methods for preparing phosphonate diesters have been
reported. Moderate to high and reproducible yields of diesters have been obtained under
mild conditions with a modified Mitsunobu protocol in which the alcohol was the
limiting reagent-for possible solid-phase synthetic application-and the modifications
included an exogenous base and electron deficient phosphines. 1 41 Also, BOP-mediated
activation of phosphonate monoesters is an efficient, racemization-free route for
preparing phosphonate diesters; this procedure is complementary to Campbell’s
Mitsunobu methodology. 1 42
Phosphonamides are, in general, more difficult to prepare than phosphonate
diesters. Nevertheless, Moroder and coworkers1'43 made significant improvements in the
synthesis of phosphonamidate peptides. They optimized the preparation of phosphono
chloridates with oxalyl chloride in the presence of catalytic amounts of DMF, which were
then either employed under AgCN catalysis or converted into the 7-aza-lhydroxybenzotriazole ester for phosphonamide bond formation. However, long reaction
times ( =14 hrs.) and moderate yields (for some of the desired compounds) were still
observed. 143

Besides their suggested acid-lability, 122,1'36' 1"37 phosphonamidates’ poor

synthetic accessibility is severely limiting the use of this interesting class of compounds
as tools in enzyme chemistry. 1 43
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Hirschmann and co-workers attempted the preparation of the phosphonamide
hapten precursor (X = NH) in Scheme I.4 . 1'33*1'34 Unfortunately, their earnest attempts to
couple D-tryptophanamide with the phosphonochloridate failed to yield the expected
phosphonamide even in the presence of AgCN (catalyst). Furthermore, efforts made to
try to couple the phosphonate monoester with D-tryptophanamide using several different
kinds of condensing agents such as diphenyl phosphorylazide and BOP reagents were
unsuccessful.

Nevertheless, they were able to couple, under AgCN catalysis, the

phosphonochloridate with (R)-(+)-P-indolyllactamide to obtain the phosphonate diester
in yields that were initially variable (0-32%).144 Preparation of the phosphonate diester
in a reproducible 40 % yield was later achieved by converting the phosphonochloridate
into a phosphonyltriethylammonium salt prior to the addition of AgCN and (R)-(+)-|3indolyllactamide (Scheme 1.5). The phosphonate diester was subsequently converted
into a hapten, which was used to induce antibodies that possess peptide ligase activity. 133
However, the synthesis of the phosphonamide hapten precursor remained elusive.
1.4 Phosphorus (HI) Synthetic Approach
The synthesis of phosphonate esters and amides from H-phosphinates by a novel
one-pot activation-coupling-oxidation/sulfurization protocol was developed in Hammer’s
laboratory. 1'45 In this approach phosphonochloridites, activated P(m) species, were used
in the key coupling step instead of phosphonochloridates, P(V) compounds (Scheme 1.6).
Since nucleophilic displacement is much faster at a P(III) center than at a P(V) center, 1 40
this new synthetic approach has the potential of increasing the yield and efficacy of
production of phosphonopeptides. This P(m) approach also permits facile design and
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preparation of phosphonates with a variety of heteroatoms around the phosphorus center
( e.g., X = NR, Y = O, Z = S or X = O, Y = S, Z = S) (Scheme 1.6) . 1 45
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p N b < \ ,0
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0
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Scheme 1.4 Synthesis of hapten precursor via P(V) coupling method
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Scheme 1.5 Modified P(V) approach for attempted synthesis of hapten precursors
Because of their air-stability, the H-phosphinates were envisioned as the ideal
precursors to the P(m)-based phosphonate synthesis. They could be easily converted to
the P(m) species with the commercially available dichlorotriphenylphosphorane
(PhsPCh).

Following activation, the phosphonochloridite could be coupled, in the

presence of base, to an amine or alcohol nucleophile and then oxidized or sulfurized.
Using this protocol, Fernandez and co-workers were able to prepare about 12 dipeptide
model compounds in moderate to good yields. 1.45
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The goal of this part of the research was to develop general conditions, employing
the P(IH)-based protocol, for preparation of the phosphonamide hapten precursor144
(described by Hirschmann and coworkers) and related sterically-hindered phosphonamide
and thiophosphonamide derivatives.

Since the P(m) strategy was successful for

preparation of dipeptide model systems, it was employed to try to increase the yield and
efficacy of production of our target phosphonodipeptides, which exemplify the
difficulties many laboratories have encountered in preparing phosphonamidate
peptides. 133’117' 146 We hoped that optimization of this protocol would result in a facile,
general method (solution- or solid-phase) for preparing simple or complex
phosphonopeptides so that they may be readily available for biological and medicinal
applications.
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1.5 Peptide Secondary Structure
The amino acid sequence of a peptide or protein is termed its primary structure;
however, the local conformation or regular folding pattern of its backbone defines its
secondary structure. 147 The pair of conformational angles, phi (<(>) and psi (\|f), of each
amino acid determines the conformation of the main chain of a protein (Figure L.3) . 1 48
%
%
\
V

or

Figure 13 Torsional angles of a peptide backbone
The most common secondary structural elements found in proteins are the a-helix, Ppleated sheet, and turns or bends. 1-47 The a-helix and P-pleated sheet are periodic
structures; they possess hydrogen-bonding patterns (main chain NH and C O groups) that
repeat at regular intervals. 1-47' 1-48 The a-helix is rodlike and involves only one continuous
peptide chain, but the P-pleated sheet, which can form a two-dimensional array, can
include one or more polypeptide chains. 1-47' 148 Besides hydrogen-bonding, the a-helix
and P-pleated sheet are generally stabilized by hydrophobic effects, Van der Waals
forces, and electrostatic forces. 149*1-51 The turns in a protein are the stretches or bends
where the polypeptide chain abruptly changes direction; they often occur at the surface of
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proteins. 1'47,1,50 Furthermore, incorporation of turns also allows a-helices and P- sheets to
be folded back onto themselves. 150 Some polypeptides assume a random coil
conformation, which is a non-repetitive structure that is flexible and statistically
random. 1'47 Random coils, however, can form reproducibly in a peptide chain. 151
The a-helix is the most prevalent helical structure found in proteins. 1'48' 151 The
consecutive residues in an a-helix all have the phi, psi angle pair at approximately -60°
and -500.1'48 In the a-helix there are 3.6 residues per turn with hydrogen bonds between
the carbonyl oxygen of residue i and the amide proton of residue i + 4, forming a 13membered ring (Figure 1.4) . 150' 151 The rise per residue of an a-helix is 1.5 A along the
helical axis, which corresponds to a rise of 5.4

A per turn. 1 48

Theoretically, an a-helix

can be either right-handed or left-handed depending on the screw direction of the chain.
However, right-handed a-helices, which are promoted by L amino acids, are almost
always observed in proteins. 148,150' 151 A left-handed a-helix is not allowed for L amino
acids due to the proximity of the side chains and the carbonyl group. 1 48
The 3io-helix, though less common than the a-helix, accounts for approximately
10 % of helical structures in proteins. 152' 1-53 The phi, psi angle pair for consecutive
residues in a 3to-helix is approximately -30° and -50°.154 In 3io-helices there are 3
residues per turn with hydrogen bonds between the carbonyl oxygen of residue / and
amide proton of residue i + 3, forming a 10-membered ring (Figure 1.4) . 153' 154 The rise
per turn in a 3io-helix is 5.8 A, which corresponds to a rise of 1.94 A per residue. A 310 helix is therefore slightly longer and tighter than an a-helix. 154
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1.6 Amphipathic a-Helix
In an amphipathic helix one face, along the helix axis, is hydrophilic while the
opposite face is hydrophobic. 1 48 The “Schiffer-Edmundson” helical wheel projection
(two-dimensional) shown in Figure 1.5 is a convenient way to illustrate the amino acid
sequence of an amphipathic a-helix. In the diagram, P represents the polar residues of
the hydrophilic face, and N represents the non-polar residues of the hydrophobic face.
The helical wheel is shown as if looking down the helix axis from the C-terminus to the
N-terminus. Since one turn in an a-helix is 3.6 residues long, each amino acid can be
plotted every 360/3.6 = 100° around a circle. 148

The structural arrangement of

amphipathic a-helices allows them to develop a barrier between non-polar regions of a
macromolecule or molecular assembly and a polar environment. 1 55 It also provides a
means for protein-protein interactions via hydrophobic interactions between two
amphipathic helices on different peptide chains. 155

Polar
Non-Polar

Face

Face

Figure 1.5 Helical wheel diagram of an amphipathic a-helix.
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Amphipathic a-helices comprise about 50 % o f the a-helices found in soluble
globular proteins. 1-56"1^ 7

They are also found in fibrous proteins like myosin and

tropomyosin, DNA-binding proteins, and smaller polypeptides such as hormones and
venom. 157 Furthermore, amphipathic peptides are exploited as part of the host defense
system of many organisms, ranging from prokaryotes to humans. 1'57' 1'58

These

antimicrobial peptides kill bacteria and other microbes presumably by disrupting the cell
membrane. 157 Several studies have indicated that the amphipathic character of
antimicrobial peptides plays a significant role in their biological activity. 1'57,1^ 9

In

addition, even short, de novo peptides (10-16 residues of varying sequences) containing
the amphipathic a-helix as the only consistent structural feature were shown to have
comparable antimicrobial activities as longer or native peptides; they also tended to
exhibit a higher degree of selectivity of bacterial killing over normal mammalian cells. 1J 9
Many naturally occurring antimicrobial peptides of broadly varying sequence
have been isolated with amphipathic helical domains as a consistent structural feature.1^9'
160

Antimicrobial peptides usually contain approximately equal numbers of polar and

non-polar amino acids within the amphipathic domains and a sufficient number of basic
residues to provide the peptide an overall positive charge at physiological pH. 159 Some
antimicrobial peptides display excellent selectivity in destroying bacteria over
mammalian cells. 159 This selectivity has been ascribed to differences in the cell
membranes of bacteria and mammals.

Bacteria exterior membranes are negatively

charged, but the exterior membranes of mammalian cells are essentially neutral. As
stated previously, antimicrobial peptides have an overall positive charge; they might
therefore preferentially bind to bacteria over mammalian cells. The cholesterol in the cell
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membranes of mammals, which could possibly inhibit membrane disruption by
antimicrobial peptides, and the lower membrane potential across mammalian cells have
also been suggested as bases for selectivity of antimicrobial peptides. 159,161
Some examples of natural antimicrobial peptides are melittin, cecropin A,
magainin 2, and alamethicin. 1 62-163 Melittin, an amphipathic peptide composed of 26
residues, is extracted from the honey bee, Apis mellifera, 162

Melittin is positively

charged (+ 6 ); its hydrophobic surface is more extensive than its narrower polar face. It
exhibits broad spectrum antimicrobial activity at micromolar concentrations, but it is very
cytotoxic. 139,162 Cecropin A is a 37-residue antimicrobial peptide isolated from the
North American silk moth, Hyalophora cecropia.

It contains two a-helical regions

extending from residues 5 to 21 (amphipathic region) and 24-37 (largely hydrophobic)
with the two helical regions lying in two planes that form an angle of 70° to 1000 . 162
Cecropin A displays excellent antimicrobial activity at concentrations that are not
cytotoxic toward mammalian cells. 1,59,1'62

Magainin

2

is a 23-residue antimicrobial

peptide isolated from the skin of the frog, Xenopus laevis. Magainin 2, like Cecropin A,
exhibits broad spectrum antimicrobial activity at concentrations not cytotoxic toward
mammalian cells. 1,62 Furthermore, both Cecropin A and Magainin 2 are unstructured in
aqueous solution but become a-helical in amphipathic media such as cell membranes and
micelles.

Alamethicin is 20-residue linear peptide of the fungus, Trichoderma

viride. 134,163 It is a member of the peptaibol class of natural antiobiotics, but it is very
toxic.

It is characterized by an acetylated N-termini, a C-terminal alcohol

(phenylalaninol), and a high percentage of a-aminoisobutyric acid (Aib) residues. It is
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noteworthy that the short peptide, Alamethicin, is highly helical due to the presence of
the high number (7) of Aib residues. 1-54,163
1.7 Significance of a, a-Dialkylated Amino Acids in Short Peptides
The occurrence of Aib-rich sequences in natural peptide antibiotics and
membrance-channel forming polypeptides has led to an upsurge of interest in the design
and synthesis of short, Aib-rich peptides with predictive secondary structure. 164' 169
Peptides containing Aib tend to favor a helical conformation.

Although several

proteinogenic amino acids are known for promoting helicity in proteins or peptides, the a,
a-dialkylated amino acid, Aib, is rather unique because it effectively confers high helicity
on short synthetic peptides of length 8 - 1 0 , which is half the length required of most other
sequences. 1'67 The allowable phi, psi angle pair for Aib occur in two very restricted
regions, located in the area of (-57°, -47°) and (57°, 47°). These two regions correspond
to a right-handed a- or 3io-helix and a left-handed a- or 3to-helix, respectively. 1 64,166
Since the Aib residue is achiral, either the L- or D- configuration is equally possible.
Chiral residues that have the L- or D- configuration therefore determine the handedness
of a helix comprised of Aib residues in the sequence. 1 64
Backbone conformations of Aib-rich peptides may display a 3i0-, a-, or mixed
3io-/a-helical pattern depending upon critical factors such as peptide length, Aib fraction,
and amino acid sequence. 164' 1 65 Karle and Balaram1 64 compiled general conformational
trends observed for 33 Aib-containing peptides (6-20 residues) in the crystalline state.
The authors suggested from their study that, in general, a 3io-helical structure is preferred
for shorter peptides and an a-helical structure for longer peptides.

A medium length of

8-10 was considered to be the 3io/a transition length for peptides possessing 50 % Aib.
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Peptides of a shorter length favor the 3io-helix while longer ones favor the a-helix. Also,
the study indicated that a large percent (> 50%) of Aib residues in a peptide induces a
3 10-helix. Similar findings were also found in other studies conducted on the crystal
structure of various peptides containing many Aib residues. 164 Basu et al. reported that
the amino acid sequence also affected the 3io/a-helix equilibrium. Their study suggested
that the a-helix is favored when two monosubstituted amino acids are next to each other,
but the 3to-helix, when no two monosubstituted amino acids are next to each other. 165
Studies have also been investigated on the effect of the solvent on the 3io/a-helix
equilibrium of Aib-rich peptides.

Several investigations (theoretical and empirical)

suggested that solvents with low dielectric constant favor 3io-helical structures, whereas
solvents with high dielectric constant are inclined to favor a-helical structures.164,167’169'
172

Until recently, these studies were limited to spectroscopic measurements of

hydrophobic peptides (e.g., oligomers of Aib) in organic solvents like chloroform and
dimethylsulfoxide or X-ray structure determinations of peptides crystallized from organic
solvents. 167,170 Yokum et al. 1 72 reported the design and synthesis of short, amphipathic
a- and 3io-helices that exhibited their designed structures in an aqueous, membrane-like
media (25 mM SDS); their peptides contained 60% Aib content and the watersolubilizing a, a-disubstituted amino acid, 4-aminopiperidine-4-carboxylic acid (Api).
They also reported that amphipathic design was primary in controlling the secondary
structure (helical preference), overriding traditional key factors such as the number of a,
a-amino acids (aaAA) and the order of the a-amino acids and aaAA in a sequence.
Toniolo et al. reported the first pure-water-soluble 3io-helical peptides, which were
comprised mainly of aaAAs and the extremely water-solubilizing, azacrown-
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functionalized

a-amino

acid,

L-2-amino-3[l-(l,4,7-triazacyclononane)]propanoic

(ATANP) . 1 69,171
1.8 Synthesis of Short, Helical Peptides
The incorporation of aaAAs into short de novo peptides promotes helical peptide
structures and increases the peptides resistance to enzymatic hydrolysis, 173 but, until
recently, the preparation of the peptides, especially peptides with sequential aaAAs, has
proven to be a very difficult task. 1'74 The aaAA couplings are inherently more difficult
because of the significantly greater steric bulk caused by the additional substituent on the
a-carbon.

The use of carbodiimides (e.g. dicyclohexyl carbodiimide (DCC) and

diisopropyl carbodiimide (DIC)), which are traditional amino acid coupling agents,
results in unsatisfactory yields for aaAA couplings. 1 75 Even longer reaction times or the
use of additives such as 1-hydroxybenzotriazole (HOBt) rarely result in good yields for
the carbodiimide-mediated aaAA couplings. Employing first-generation uranium salts
(e.g., 0-(benzotriazol-1-yl)-1,1,3,3-tetramethyIuronium hexafluorophosphate (HBTU))
and phosphonium salts (e.g., benzotriazol-l-yloxy-tris(dimethylamine) phosphonium
hexafluorophosphate (BOP)) along with extended reaction times or application of heat
also usually yielded only moderate results for aaAA couplings. 1'72,176
Alternate coupling protocols or reagents have been employed in an attempt to
improve the unsatisfactory results often observed in aaAA couplings.

Some of the

methods or reagents employed are the following: fluorenylmethyloxycarbonyl-JVcarboxyanhydrides (Fmoc-NCAs), azirine method (e.g., 2-(dimethylamino) 3,3-dimethylazirine), and acid chlorides. All of these methods have the potential of producing
improved synthetic results for aaAA couplings, but their use have been limited because
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of specific drawbacks. The use of Fmoc-NCAs often result in side-product formation and
moderate to low yields. 1'76 The azirine method is limited because of the post coupling
acid hydrolysis, which is detrimental to peptides containing acid labile protecting groups,
often required for the resulting C-terminal amide. 1 65 The use of acid chlorides is very
effective for coupling aaAAs, but the harsh, acidic conditions employed for the
formation of acid chlorides also often limit them to amino acids containing no acid labile
protecting groups. 1'77 Also, the formation of oxazalones, which could lead to
racemization, is often associated with acid chlorides. Overall, none of these alternate or
traditional methods are capable of producing sequential aaAA couplings in high yields
under general, mild conditions, such as that required for high-purity sequences in solidphase peptide synthesis (SPPS) . 1-54
New and improved methods have been developed for efficient coupling of
sequential aaAAs. Carpino’s acid fluoride coupling was the first method to give high
yield couplings of sequential aaAAs under mild conditions both in solution and solid
phase. 177"1'78 In contrast to acid chlorides, a wide range of protection schemes can be
employed with the mild, acid fluoride method. An Acid fluoride synthesis is usually
accomplished by coupling a preformed amino acid fluoride (4 equivalents) with the free
amine of an amino acid in the presence of

2

equivalents of base like NJV-

diisopropylethylamine (DIEA). Acid fluoride itself is prepared by treating an amineprotected amino acid with cyanuric fluoride ( 2 equivalent) and pyridine ( 1 equivalent) . 179
In addition, a method for the in situ generation of an amino acid fluoride with
tetramethylfluoroformamidinium hexafluorophosphate (TFFH) and subsequent coupling
conditions has been developed; good, comparable results have been observed. 1 80
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More recently, uronium salts based on l-hydroxy-7-azabenzotriazole (HOAt)
such as {N-[(dimethylamino)-iH-l,2,3-triazolo[4,5-b]pyridin-l-ylmethylene]-N-methylmethanaminium hexafluorophosphate iV-oxide (HATU) have exhibited significant
advantages for the coupling of sterically hindered amino acids in terms of improved
coupling yields and acylation rates and decreased racemization. 181*182

Also, the

phosphonium-based analog of HATU, 7-azabenzotriazol-l-yloxytris(pyrrolidino)phosphonium hexa-fluorophosphate (PyAOP) have also been reported to be very useful for
the solid-phase preparation of peptides incorporating hindered amino acids. 1 83 Overall,
both the second generation uranium salt (HATU) and phosphonium salt (PyAOP) are
excellent reagents for aaAA couplings. However, PyAOP, relative to HATU, is more
advantageous because of the formation a less toxic side-product (phosphoramide) and
because excess PyAOP (in contrast to HATU) doesn’t participate in any chainterminating side reactions at the amino terminus. 1 83
1.9 Circular Dichroism Spectroscopy
Several methods such as X-ray crystallography, NMR, electron spin resonance,
and circular dichroism (CD) spectroscopy have been employed in peptide secondary
structure determination. 184 However, due to its convenience and reliability, CD has
become the method of choice for identifying global peptide secondary structure. 1 85 CD
spectroscopy is a technique that measures the difference in absorbance of right- and leftcircularly polarized light by an asymmetric substance. 1 86 Peptide secondary structure can
be determined by CD in the “far-UV” spectral region (180-250 nm); at these wavelengths
the chromophore is the peptide bond. 185' 1 87 As seen in Figure 1.6, the major categories
of peptide conformations (random coil, P-sheet, and helices) are distinctly different. 1 88
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The random coil displays a minimum near 195 nm and a maximum near 217 nm, whereas
the P-sheet is distinguished by a positive band around 195 nm and a negative band
centered about 217 nm. Both 3io and a-helical peptides give rise to negative CD bands
around 222 nm (n—mi*) and 207 nm (ti—mi*). A positive band around 191 nm (7t-Mt*) is
also characteristic of both types of helical peptides, although it is usually much weaker in
3 io helical peptides. 1 89 The ratio R of the intensity of the negative bands, where R =
is a generally accepted parameter used to distinguish a 3io-helix from an
a-helix. For an a-helix R = 1, but for a 3io helix R = < O.4. 1 89
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Figure 1.6 CD spectra of poly-L-lysine in the a-helical, P, and random conformations.
CD spectroscopy played an integral role in the general goal for this part of our research
on peptide analogs. We were primarily interested in the design and efficient synthesis of
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short, amphipathic 3io-helical peptides that are able to retain good antimicrobial activity
and low cytotoxicity. With CD, we could analyze the solvent (aqueous-organic) effects
on the 3io-/a- helix equilibrium on our designed, amphipathic 3to-helical peptides, as well
as correlate observed secondary structure in various media (e.g., SDS and pure water)
with bioactivity.
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Chapter 2
Synthesis of Phosphonamides and Thiophosphonamides by a One-Pot ActivationCoupling-Oxidation Procedure
2.1 Introduction
Phosphonopeptides are peptide mimics2 1 1 2 that emulate high-energy tetrahedral
transition states of enzyme-catalyzed peptide hydrolysis reactions. Thus, they are useful
as mechanism-based inhibitors of aspartyl

0

“I

*1 i

and metallo-proteases.

^ dL

Several

phospho-nopeptides have also shown powerful antibacterial activity.2 7 1 8 More recently,
these types of compounds have been applied to hapten design for the generation of
catalytic antibodies that possess peptide ligase activity.2-9 In this chapter we report the
synthesis of phosphonamide dipeptides la-d (R = Cbz) (Scheme 2.1) in isolated yields up
to 30 % using our P(m) one-pot activation-coupling-oxidation procedure.2-10 Previous
attempts to prepare the hapten precursor la from P(V) phosphonochloridate 2 and Dtryptophamide under standard and optimized conditions were unsuccessful, due in part to
the steric bulk of the amino acid side chains.2-11' 12 The problems of preparing the hapten
precursor la

v
"xOpNb

“ • V p;ci
o-CgH-ji
2 X=0
3 X = ..
la X = O, Y = NH2
lb X = S,Y = NH2
1c X = O, Y = OCH3
Id X = S, Y = OCH3
R = Fmoc or Cbz
Scheme 2.1 Retrosynthethic analysis of phosphonamides
and thiophosphonamides la-d
30
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exemplify the difficulties many laboratories have encountered in preparing phosphonamidate peptides via P(V) coupling protocols.2' 13*16 The P(m) method detailed herein
using phosphonochloridite 3 as the key intermediate may provide a general approach to
preparing complex phosphonamide peptide analogs for a variety of applications.
2.2 Results and Discussion
The air-stable precursor used for generation of phosphonochloridite 3 is racemic,
carbamate-protected H-phosphinate amino acid 4 (Scheme 2.2) as a diastereomeric
mixture of para-nitrobenzyl (pNb) esters. The H-phosphinate 4, under certain conditions,
was converted to the phosphonochloridite 3 with the commercially available dichlorotriphenylphosphorane (PI13PCI2). Because the solvent pyridine and the solvent system
CH2Cl2/Et3N worked well in our model systems,2-10 they were initially employed during
activation of 4 with PI13PCI2 . However, only a small amount of the phosphonochloridite
3 (3,P = 200 ppm) admixed with several other as yet unidentified products formed. This
may be due to the amide functionality in 4 being possibly sensitive to the combination of
PhsPCh with Et3N or pyridine (when used as solvent). PhjPCh in the presence of Et3N is
known to convert secondary amides to imidoyl chlorides.2-17

Mechanistically, the

formation of an isocyanate from the carbamate functionality with Ph3PCh/ EtjN is also
possible. We therefore searched for alternative solvent conditions for the activation step.
In standard P(V) chemistry, successful conversion of a phosphonate monoester to
the corresponding phosphonochloridate with thionyl or oxalyl chloride is often done in
the absence of base.2-111*2-12-2-18*2-20 Therefore, in an analogous attempt to improve the
activation step of our P(HI) protocol, treatment of 4 with PhsPCh was carried out in the
absence of base. Only two phosphorus signals, 193 ppm (activated P(m) species) and
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40 ppm (Ph3PO+ HCT) resulted. After activation, we proceeded to the next step of
coupling, followed by oxidation or sulfurization. Several attempts to isolate or purify the
resulting dipeptides by column chromatography (silica and alumina under various solvent
conditions) were generally unsuccessful.
pNbO

O

CbzHN^

pNbO
Ph3 PCI2

CbzHN

+

c-CjH,,

i-CjH,,

4

3

ph3p

0

Scheme 2.2 Activation of H-phosphinate 4 to form phosphonochloridite 3
The difficulty in isolation of the phosphonodipeptides from the silica column was
initially attributed to the general acid lability of phosphonamides.215,2'21’2'22 However,
only about 0-3 % of the sulfurized species (3lP = 75-80 ppm) sometimes eluted from the
alumina (basic or neutral) column. Furthermore, triphenylphosphine oxide tended to
smear the columns; therefore, it was often observed in every collected fraction.
Oftentimes Ph;jPO was the only substance to elute.
In an effort to find a solution to the synthetic or isolation problems associated
with preparation of 1, experiments (P (III) protocol) were conducted using 4 and less
complex nucleophiles like benzyl alcohol, methyl-S-lactate, leucine methyl ester, and
benzylamine. hi the crude mass spectra (FAB) of these less complex phosphonate esters
and amides, the parent ions minus the pNb group were readily observed.

Further

examination of the FABMS of the crude reaction mixtures containing our synthetic
targets la-d also revealed that the major products appeared to be ones in which the pNb
group had been cleaved off. It was therefore postulated that the pNb group of these
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simple phosphonate derivatives as well as our targets

1

was possibly being cleaved

during one of the three steps of the P (HQ-based protocol.
I l l Examination of Activation Reaction
Upon further inspection of 3IP NMR spectra from the activation step without any
base, it was speculated that the activated species at 193 ppm was not the desired P (ID)
species 3. In acidic medium the major side product, PI13PO, resonated at 40 ppm, but,
upon addition of base, it shifts back upfield to 27 ppm, where it normally resonates in
neutral or basic milieu. Conversely, the activated P (HI) species at 193 ppm, upon
addition of base, doesn’t move to the downfield chemical shift of 2 0 0 ppm expected in
basic media. From this simple 31P spectra analysis and difficulties with isolation of la-d,
we proposed that activation in the absence of base forms 3 but quickly converts, after
pNb cleavage, to the respective phosphonodichloridite (3IP = 193 ppm); para-nitrobenzyl
chloride (pNbCl) was also thought to form in this process (Scheme 2.3).
To validate the hypothesis of pNb cleavage during activation, a study was
conducted on the activation step using 4 and GC-MS analysis of the products. Reaction
of 4 with PhsPCh in CH2CI2 in the absence of base produced an intense peak
corresponding to 4-nitrobenzyl chloride (-1:1 ratio with PhjPO). In contrast, when this
reaction was performed with pyridine present (-1.5 equiv.), the peak corresponding to 4nitrobenzyl chloride was very weak (<5 % the intensity of PhjPO) (Figure 2.1). It was
therefore concluded that in order to prevent pNb cleavage, the presence of base to
scavenge generated HC1 during the activation reaction was essential.
The best solvent/base combination for activation of 4 with PI13PCI2 was finally
determined to be two equivalents of pyridine (~ 3%) in CH2CI2. With one equivalent of
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Scheme 2 3 Proposed route for phosphonate ester cleavage and phosphonamidate
formation

(A)

<.N

I.N

PhjPO
( -1 7 min)

I.H

U.H

U ,«

14.M
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(D)

pNbCI
(—11 min)

Figure 2.1 Comparative GC-MS study of activation step. (A) Sample from activation of
4 in the absence of base with extensive ester cleavage evidence by side-product, pNbCI.
(B) Sample from activation of 4 in the presence of pyridine with minimum ester
cleavage. (C) Mass Spectrum of peak - 17 min. (PI13PO). (D) Mass Spectrum of peak
~ ll (pNbCI).
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pyridine nearly equal amounts of 3 (3,P = 200 ppm) and the P(IH) species (3lP = 193
ppm) that resulted from pNb cleavage formed. Furthermore, as the number of equi
valents of pyridine increased from 2 to huge excess (e.g., pyridide as solvent), the number
and amount of side-products increased (Table 2.1). However, with the optimized solvent
condition, very little or no side products were evident from 3IP NMR.
Table 2.1 Phosphonochloridite generation under various solvent
and base conditions
Base (equiv.)

Solvent

Ph3PCl2a

Pyridine

2.5*

Solvent

200 (0.25), 180 (0.05), 165
(0.04), 158 (0.15), 120 (0.18),
115 (0.05), 39-41 (0.08), 28 (1))

CH2C12

2.5*

NEt3 (2)

same as above

CH2CI2

2 .0 *

none

193 (0.4), 40* (1)

CH2CI2

1.5*

pyridine ( 1 )

200 (0.3), 193 (0.4), 28 (1)

31P

8

ppm (ratiof

1 .2 *
pyridine (2 )
200 (0.85), 28 (1)
CH2CI2
a Contains 10-20 %Pti3PO
* Represent number of equivalents needed to consume 4
c Represent intensity of each peak relative to Ph3PO
d PhjPOTlCr

2.2.2 Coupling Step
The next step of the one-pot procedure was the coupling of 3 to Dtryptophanamide 5a or D-tryptophan methyl ester 5b to form the phosphonamidite

6

(Scheme 2.4, Path A). The major problem initially encountered with the amine coupling
of 5 to 3 was the formation of an unknown substance (3IP = 180 ppm) that competed with
the formation of the phosphonamidite 6 . When 5 was added in one portion to the
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phosphonochloridite 3, only the 31P signal around 180 ppm was observed. However,
when 5 was added over 15-20 minutes, the intensity of the peak ~ 180 ppm and the four
possible diastereomeric peaks (3 IP, 123, 124, 126, 128 ppm) was nearly equal. We
therefore directed our investigation toward elucidating the identity or properties of that
unknown species (31P =180 ppm).
c-CgHu
CbzHN

A

-c i
OpNb

Path A
H-D-Trp-YHCl
DIEA
5a Y = NH,
5b Y = OCH,

Indole
pNbO
CbzHN

y v yO

c-C6 Hu
6a
6b

Path B

Y

Y = NH2
Y = OCH-i

DIEA
t-BuOOH
or

S8
Indole
pN b(\ , .X
.

?
Y

T
c-C6Hu

la
lb
lc
Id

S

'Y
1
O

X = 0 ,Y = NH2
X = S, Y = NH2
X = 0 ,Y = 0CH 3
X = S, Y = OCH3

Scheme 2.4 Synthesis of la-d via Path A or Path B
In the presence of tertiary amines urethane-protected amino acids and peptides are
known to cyclize to form oxazolones,2'23 which are themselves reactive acylating agents.
We reasoned that similar cyclization could be occurring with our urethane-protected
phosphonochloridite 3 to form an oxazaphospholine2' 19 (3lP = 180 ppm). We generated
the proposed oxazaphospholine 7 (Scheme 2.4, Path B) by adding 1.5 equivalents of the
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tertiary base, diisopropylethylamine (DIEA), to 3. To investigate the reactivity of 7, the
nucleophile 5a or 5b was added in one portion. After about 15 minutes, two phosphon
amidite diastereomers preferentially formed, which, after sulfurization or oxidation,
resulted in 1 as a mixture of two diastereomers (Figure 2.2, Figure 2.3, and Figure 2.4);
they were isolated using reverse-phased HPLC (Figure 2.5 and Figure 2.6).
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Figure 2 2 3lP NMR spectra: a. Reaction of H-phosphinate 4 with PhjPC^ in presence
of pyridine (2 equiv.) to form phosphonochloridite 3 (-200 ppm); unreacted 4 is - 36 and
37 ppm and PhsPCU ~ 64 ppm; peak ~ 28 ppm is Ph3PO in each spectrum b. Proposed
oxazaphospholine 7 (- 180 ppm), c. Species 6 a (~ 123.6 and 124.9 ppm), d. Target lb
(87.2 and 88.3 ppm), e. Target l a (~ 29 and 30 ppm).
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Figure 2.5. Analytical HPLC purity check of isolated la and lb . HPLC was carried out
on a Supelco 5 pm C-18 reversed-phase column (0.21 x 25 cm) using a mobile phase of
0.1 M TEAA buffer (pH = 7) and CH3CN (10 % v/v, 0.05 M aqueous TEAA) with a
gradient of 50-100 % of the organic phase over 50 min and a flow of 1 mL/min. (A).
Cbz-Cyclohexyl \|f|P (O) (OPNB) NH] Trp-Mfe la; tR= 10.7 min; purity 82 %. (B).
Cbz-Cyclohexyl \j/[P (S) (OPNB) NH] Trp- NH2 lb; tR= 19.2 min; purity 95 %.
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Figure 2.6. Analytical HPLC purity check of isolated lc and Id. HPLC was carried out
on a Supelco 5 tun C-18 reversed-phase column (0.21 x 25 cm) using a mobile phase of
0.1 M TEAA buffer (pH = 7) and CH3CN (10 % v/v, 0.05 M aqueous TEAA) with a
gradient of 50-100 % of the organic phase over 50 min and a flow of 1 mL/min. (A).
Cbz-CyhGly y[P (O) (OpNb) NH] Trp-OMe lc; tR= 17.7 min; purity 90 %. (B). CbzCyhGIy \|f[P (S) (OpNb) NH] Trp-OMe Id; tR= 29.2 min; purity 95 %.
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It is interesting to note that the activation of the H-phosphinate ester 4 (3IP = 36
and 37 ppm) resulted in the formation of only one peak (3lP ~ 200 ppm) for the resulting
phosphonochloridite 3. We proposed that the expected two diastereomers of 3 resonated
at the same chemical shift. However, the formation of only two diastereomers of 1
instead of the expected four may be due in part to the formation of only the trans
conformer (plus its enantiomer) of 7: the observed, one peak (3lP -1 8 0 ppm) of 7 could
possibly correspond to one pair of enantiomers (e.g., R, S and S, R). The cis conformer
(e.g., enantiomers R, R and S, S) appears to be more sterically crowded (Figure 2.7);
therefore, its possible instability may have precluded its formation.
NO-

BnO
BnO

Cis

Figtire 2.7 Trans and Cis conformer of oxazaphospholine 7
The proposed oxazaphospholine 7 was also coupled to the amine nucleophiles,
leucine methyl ester and glycine ethyl ester, and the alcohol nucleophiles, benzyl alcohol
and methyl (5)-lactate. Coupling of 7 to leucine methyl ester 8 and glycine ethyl ester 9
resulted in the formation of the phosphonamidites 10 (3IP = 124.9, 126.1 ppm) and 11
(3IP = 126.5 ppm), repectively. Sulfurization of 10 and 11 formed the thiophosphon
amides 12 (31P = 86.9,88.3 ppm) and 13 (31P = 89.7 ppm), respectively; oxidation of 11
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formed the phosphonamide 14 (3IP = 39.2 ppm) (Scheme 2.5, Figure 2.8). Coupling of 7
to benzyl alcohol 15 and methyl-S-lactate 16 resulted in the formation of the
phosphonates 17 (3lP = 178.7 ppm) and 18 (3lP = 179.8, 179.9 ppm), respectively.
Sulfurization of 17 and 18 formed the thiophosphonamides 19 (3lP = 97.1 ppm) and 20
(31P = 95.5,96.9 ppm), respectively (Scheme 2.6, Figure 2.9).

H-L-‘Leu-OMe • HC1

8

CbzH

7
H-Gly-OEt • HC1
9

pNbO^
CbzHN^ ^ P

CbzHN
11
12

or
t-BuOOH

pNbO^ x
CbzHN.

13 X = S
14 X = 0
Scheme 2.5 Synthesis of Cbz-protected thiophosphonamides 12-13 and
phosphonamide 14.
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An alternative structure was explored for the phosphitylating agent (3lP = 180
ppm). We speculated that the observed reactive species could also possibly be analogous
to the previously unrecognized phosphonyltrialkylammonium salts of Hirschmann and
co- workers.2' 11' 2' 12 To test that hypothesis, we tried to generate the phosphitylating agent
(3IP = 180 ppm) by adding the phosphonochloridite 3 to PS-DIEA resin (DIEA attached
to a polystyrene resin). We reasoned that if a reactive phosphinyltrialkylammonium salt
forms, then it would remain attach to the resin. However, after the reaction mixture was
filtered from the resin, the newly formed phosphitylating agent was found in solution, not
attached to the resin (Scheme 2.7, Path A vs. Path B). Therefore, we concluded that the
reactive species that resonated around 180 ppm wasn’t a phosphinyltrialkylammonium
salt but possibly indeed the initially proposed oxazaphospholine 7.
BnOH
15

p N b (\
CbzHN

17

CbzHN

CbzHN
18
19

CbzHN

20

Scheme 2.6 Synthesis of thiophosphonate diesters 19-20
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Figure 2.8 3IP NMR spectra of thiophosphonamides 12*13 and phosphonamide 14 after
isolation. (A) Compound 12 after isolation by pressure alumina chromatography. (B)
Compound 13 after isolation by reverse-phase chromatography. (Q Compound 14 after
isolation by reverse-phase chromatography.
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Figure 2.9 31P NMR spectra of phosphonates 19-20 after isolation. (A) Compound 19
after isolation by normal-phase chromatography. (B) Compound 20 after isolation by
reverse-phase chromatography.
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Scheme 2.7 Synthesis of oxazaphospholine 7 via PS-DIEA resin.
To prepare the final products la-d, 12-14, and 19-20 in Table 2.2, we first generated the
proposed phosphitylating agent 7 from the phosphonochloridite 3 and two equivalents of
DIEA. Then an amine or alcohol nucleophile was coupled to 7 to form a
phosphonamidite or phosphonite followed by sulfurization or oxidation with elemental
sulfur or t-butylhydroperoxide, respectively. Alternatively, we found that by adding two
equivalents of 5 with 4 equivalents of DIEA to the phosphonochloridite 3 followed by
oxidation or sulfurization also results in the formation of 1, but, as a mixture of four
diastereomers instead of two (Figure 2.10). With this method, the proposed oxaza
phospholine wasn’t observed; however, we strongly believe it still partially formed
during the coupling step but quickly reacted with 5 to aid in forming the resulting
diastereomers of la-d.
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Table 2.2 Synthesis of phosphonamides and thiophosphonamides
Nucleophile

Entry

X

Product

31p

% yield*

1

5a

0

la**

18

28.8,29.4

2

5a

s

lb*b

14

85.3,86.6

3

5b

0

lc**

15

30.5,30.8

4

5b

s

Id**

30

88.4,87.3

5

8

s

12*,r

28

86.9,88.3

6

9

s

13**

26

89.7

7

9

0

14**

21

39.2

8

15

s

1 9 b4

15

97.1

95.5,96.9
30
s
20**
9
16
r r.
TT-.T b __ ■
.ruif.
“ Isolated using reversed-phase HPLC 0 characterized by SlP NMR, lH NMR, and MS
(FAB). c Purified by pressure alumina chromatography. d Purified by flash (silica)
chromatography. * Isolated yield.
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Figure 2.10 31P NMR of alternate procedure for preparation of Id. A. Reaction of Hphosphinate 4 with PI13PCI2 in presence of pyridine (2 equiv.) to form phosphonochlo
ridite 3 (-200 ppm); unreacted 4 is - 36 and 37 ppm and PI13PCI2 - 64 ppm; peak - 28
ppm is PI13PO in each spectrum. B. Coupling of 5b directly to 3 to form phosphonamidites 6b as mixture of diastereomers. C. Sulfurization of 6b to form Id as a mixture
of four diastereomers (85.9,86.7,87.2, and 88.3 ppm).
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Figure 2.11 Generation of oxazaphospholine 7 via PS-DIEA resin. A. Reaction of Hphosphinate 4 with PI13PCI2 in presence of pyridine (2 equiv.) to form phosphonochloridite 3 (~200 ppm); unreacted 4 is ~ 36 and 37 ppm and PI13PCI2 ~ 64 ppm; peak - 28
ppm is Ph3PO in each spectrum. B. Reaction of PS-DIEA resin (3.68 mmol/g, 2
equivalent) with 3 to form 7 in solution; no 3lP signal observed on resin after reaction.
2.23 Role of Amine-Protecting Group
If oxazaphospholine formation is undesired (e.g., result in low coupling efficiency
or racemization of products) in a phosphonopeptide synthesis, the use of a different kind
of amine-protecting group may be a logical solution. We investigated the non-urethane
protecting

groups

2-nitrobenzenesulfonyl

cyclohexanedione (Dde) (Figure 2.12).

(Nbs)

and

5,5-dimethyI-2-acetyl-l,3-

According to Miller and Scanlan,2-24 Nbs-

protected amino acid chlorides are not capable of oxazolone formation. Bycroft et al.2~25'
226 concluded that the Dde-protecting group precludes racemization via the common
oxazolone mechanism observed with urethane amine-protecting groups. Both amineprotecting groups (Nbs and Dde) can be removed under relatively mild conditions. The
removal of the Nbs group2'24’2'27can be accomplished with PhSH/K2CC>3 in DMF and the

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

48
removal of the Dde2*25*2-26 group with 2% hydrazine in DMF. Furthermore, the Dde
group can be used orthogonally with both Fmoc and Boc protection in solution and solidphase peptide synthesis. We prepared the Nbs- and Dde-protected H-phosphinate amino
acid esters 21 and 22 and activated them with PI13PCI2 (Scheme 2.8). As with the Cbzprotected phosphonochloridite, we also

treated the Nbs- and Dde-protected

phosphonochloridite 23 and 24, respectively, with DIEA. With the Nbs species, a tiny
peak around 180 ppm along with a myriad of other small peaks (downfield and upfield) is
usually observed. In this case we believe that deprotonation of the sulfonamide proton is
occurring which could lead to a variety of other possible side reactions such as
cyclization to a five- or three-membered ring or possibly some type of polymerization
reaction (Scheme 2.9). In the case of the Dde-species, no peak was observed around 180
ppm, but several upfield peaks were observed. We believe that the Dde group may have
been prematurely cleaved by DIEA, which is a stronger base hydrazine (used to cleave
Dde) (see Scheme 2.10 and Scheme 2.11). Self-condensation is one side-reaction that
may have occurred as a result of Dde cleavage.

o

N bs

D de

Figure 2.12 Non-urethane amine-protecting groups

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

49

" • V

pNbqx
Ph3Pag

RH(y

iS a

o-QgHii

0

^ p = nfe
22R = D de

^

■

Q5 H11

hhn^
0

p^

> "
A

^

Q 3H 11

2 3 ^= ^
24R =D de

och,

O

25R =N bs
26R = Dde
X = S, ■ ■
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Scheme 2.11 Proposed cleavage mechanisms for Dde-protected phosphonochloridite
However, coupling 8 (2 equiv. 8 with 2 equiv. DIEA) to the Nbs-protected
phosphonochloridite

resulted

in

the

expectant

diastereomeric

mixture

of

phosphonamidites 25 (X = ") (Figure 2.13) along with a small peak around 180 ppm
(proposed oxazaphospholine); the intensity of the latter peak was much less than the
intensity of the same peak that resulted from the cyclization of the Cbz-protected
phosphonochloridite. The formation of the oxazaphospholine could be further reduced
by the slow addition

(-15-20

min.) of the nucleophile to

Nbs-protected

phosphonochloridite. With the Dde-protected phosphonochloridite, the peak at 180 ppm
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wasn’t observed during coupling of 8, but the overall coupling reaction (Figure 2.14)
didn’t proceed as well as the reaction with the Nbs phosphonochloridite.
Although

cyclization

wasn’t

expected

with

the

Nbs-protected

phosphonochloridite 23, we do believe that it formed to a small extent (evident by 3lP
~180 ppm) during the coupling of 8 to 23 in the presence of DIEA. Interestingly, in
contrast to Cbz-protected phosphonochloridite 3, cyclization to the proposed
oxazaphospholine doesn’t

occur to a great extent

with

the

Nbs-protected

phosphonochloridite upon addition of two equivalents of DIEA (before coupling). Since
very minimal cyclization is observed with 23 in the presence of DIEA, the Nbs group
could be employed in phosphonopeptide synthesis with potentially very little
racemization.
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Figure 2.13 31P NMR spectra of one-pot procedure with Nbs-protected H-phosphinate
21. A. Reaction of 21 with PI13PCI2 in presence of pyridine (2 equiv.) to form a Nbsprotected phosphonochloridite (~197 ppm); peak ~ 28 ppm is PhjPO in each spectrum B.
Coupling of 8 (2 equiv)/DIEA (2 equiv) to Nbs-protected phosphonochloridite to form
four phosphonamidites (~ 123-127 ppm);peak ~ 180 ppm corresponds to a proposed
oxazaphospholine. C. Sulfurization of phosphonamidites to form thiophosphonamides
(85.4,85.8, 86.2,86.9 ppm); peaks at 75.5 and 76.5 ppm are thiophosphonate acid esters
that are form from sulfurization of unreacted ester 21 in the mixture.
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Figure 2.14 3tP NMR spectra of activation and coupling step of one-pot procedure with
Dde-protected H-phosphinate 22. A. Reaction of 22 with PhsPCfe in presence of pyridine
(2 equiv.) to form a Dde-protected phosphonochloridite (-196 ppm); peak - 28 ppm is
PI13PO in each spectrum B. Very poor coupling of 8 (2 equiv)/DEEA (2 equiv) to Ddeprotected phosphonochloridite to form barely noticeable coupling species - 123 ppm.
The 3lP spectra in Figures 2.10 and 2.13 resemble each other. In Figure 2.10, the
oxazaphospholine 7 wasn’t purposely generated, like in Figure 2.2, before aminecoupling. However, we strongly believe that it still partially formed during coupling (2
equiv. of 5b with 4 equiv. of DIEA) but quickly reacted with the amine nucleophile to
form the diastereomeric mixture of phosphonamidites. This is based on the following
observation: when two equivalents of 5b along with only two equivalents of DIEA was
allowed to react with the phosphonochloridite 3, 3IP peaks corresponding to both the
oxazaphospholine 7 and the expected diastereomeric mixture of phosphonamidites
formed to a substantial extent. Conversely, based on data explained above, the formation
of an oxazaphospholine plays a very minimal, if any, role during the coupling step of a
Nbs-protected phosphonochloridite. Nevertheless, in both Figure 2.10 and Figure 2.13,
thiophosphonamides, as a mixture of four diastereomers, is observed.
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2.2.4 Use of Resin-bound PhjPCh
We investigated the potential of a triphenylphosphine-polystyrene resin, on which
the activating agent PI13PCI2 can be generated, in the synthesis of our compounds. We
were attracted to the resin-bound PI13PCI2 because one of the major contaminants, PI13PC),
of our one-pot procedure would remain attached to the resin after filtration. The resinbound PhjPCk2-28 was prepared by treating the PS-PPh3 resin (in glovebox) with one-half
equivalent of triphosgene (Figure 2.15).

As with our solution-phase synthesis, we

initially used two equivalents of pyridine with the H-phosphinate ester 4 during activation
with the resin. However, only a tiny activation peak along with other peaks around 19,
35-40, and 165 ppm were observed. Basically, the same types of spectra were observed
when 1-1.5 equivalents of base were used during activation. Because the reactions were
performed in a glovebox under argon pressure, we reasoned that much less base is
probably required during activation because of possible removal of some of the generated
HC1 by the continuous flow of argon. The activation reaction was then tried with only
0.5 equivalent of pyridine. One peak at 195 ppm resulted. D-Tryptophan methyl ester
was added to the filtered solution containing the activated species (3 tP, 195 ppm). Two
coupling peaks (—135 and 136 ppm) resulted (noisy baseline). After sulfurization, a tiny
peak (-80 ppm) corresponding to the sulfurized species along with several upfield peaks
were observed (Figure 2.16 and Scheme 2.12). FABMS of the crude reaction mixture
indicated a tiny m/e peak corresponding to the desired compound minus the pNb group.
Therefore, ester cleavage must have occurred during the activation step. Nevertheless,
the use of this resin appears to be very promising for the facilitation of the synthesis and
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partial purification of phosphonopeptides once the activation conditions has been clearly
determined or optimized.
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Scheme 2.12 Use of triphenylphosphine-polystyrene resin in preparation of Id
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Figure 2.15 Generation of resin-bound PhjPCh. A. Triphenylphosphine (-6.4 ppm)
polystyrene resin contaminated with small amount of Pti3PO (27.2 ppm). B. Reaction of
Ph2P-PhPS with triphosgene to form resin-bound PhjPCh (60.7 ppm).
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Figure 2.16 31P NMR spectra of one-pot procedure with resin-bound PhsPCh. A.
Reaction of H-phosphinate ester 4 with CfePPhr-PhPS. B. Coupling products (~ 135 and
136 ppm) resulting from the addition of D-tryptophan methyl ester to the activated
species (195 ppm); unidentified side-product (28 ppm). C. Sulfurized product (81.8
ppm), determined to be Id minus the pNb group.
2.2.5 Synthesis of Protected a-Amino-Alkyl-H-Phosphinate Esters
The 1-aminoallcylphosphonous acid 29 was the starting point for the synthesis of
the amine-protected H-phosphinate amino acid esters. Compound 29 was prepared
according to a procedure adapted from Baylis et al.2'29 Reaction of the hypophosphonite
salt 27, which is formed from a reaction of hypophosphorus with benzhydrylamine, with
cyclohexane aldehyde produced the diphenylmethylaminoalkylphosphonous acid 28.
The latter acid was subsequently deprotected in refluxing HBr to afford 29 in 61% yield
(Scheme 2.13).
Scheme 2.14 outlines the synthesis of Z- or Cbz-protected phosphonous acid 30
and Nbs-protected phosphonous acid 31. A procedure developed by Dumy et al230 was
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employed. They were prepared primarily by adding a solution of N-(benzyloxycarbonyl) succinimide or 2-nitrobenzenesulfonyl chloride in dioxane to a solution of 29
in water at a controlled pH (9-9.5 using 4 N NaOH). Compound 30 and 31 were obtained
in 77% and 76% yield, respectively.
Dde-protected phosphonous acid 32 was prepared according to a procedure
described by Bolin et al.231 In general compound 29 and TMS-C1 were refluxed in
CH2CI2 for 2 hours and then, after cooling to 4 °C, 5,5-dimethyl-2-acetyl-l,3cyclohexanedione and DIEA were added. Compound 32 was obtained in a 37% yield.
Esterification of the protected phosphonous acids 30 and 31 (Scheme 2.14) and 32
(Scheme 2.15) were prepared according to a procedure described by Sampson and
Bartlett.2'32 To a solution of 30, 31, or 32 in CH2CI2

was added EDC. The H-

phosphinates 4, 21, and 22 were formed as mixture of two diastereomers in yields of
82%, 94%, and 56%, respectively.
O
H

H

+

Ph2CHNH2

CH3CH2OH

Ph2CHNH3+H2P02*
27
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CH3CH2OH

c-CgHnCOH

O

O
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Scheme 2.13 Synthesis of 1-aminoalkylphosphonous acid 29
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23 Conclusions
We developed conditions, based on a one-pot activation-coupling-oxida•y m

tion/sulfurization protocol,

for preparation of sterically hindered phosphonamide and

thiophosphonamide dipeptides. It was determined via a GC-MS Study that the presence
of 2 equivalents of pyridine during activation of our H-phosphinate amino acid ester 4
with PhsPCh was necessary to prevent ester cleavage; however, using excess base (more
than 2 equivalents) or a base that is too strong (e.g., triethylamine) could result in the
formation of several side-products (evident from 31P NMR).

We proposed that an

oxazaphospholine was forming during the coupling step and was competing with the
formation of the desired phosphonamidites. After discovering that it was a reactive
phosphitylating agent, it was purposely generated by addition of DIEA to 3 before
addition of a nucleophile. This coupling route generally led to the formation of two
coupling, diastereomeric products instead of the possible four. This was attributed to, in
part, to the formation of only the trans conformer (plus its enantiomer) of the
oxazaphospholine 7. Oxidation and sulfurization were easily accomplished with tbutylhydroperoxide and elemental sulfur, respectively. Using our developed conditions,
we prepared the previously inaccessible phosphonamide la (hapten precursor) and
related derivatives lb-d.

We also applied our method to the preparation of the

thiophosphonates 19-20, thiophosphonamides 12-13, and phosphonamide 14. Compound
12 and 19 were purified by flash chromatography, but the other products were purified by
reverse-phase HPLC. All of the final products were characterized by 3IP NMR, *H
NMR, and FABMS.
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2.4 Experimental Material
2.4.1 Technical Information
Unless otherwise indicated, materials were purchased from commercial suppliers and
used without further purification. All reactions were performed in dry glassware under
an atmosphere of argon. Triethylamine was dried by refluxing over CaH2 and distilling
directly onto dry molecular sieves (3A). Anhydrous dichloromethane, pyridine, and
diisopropylethylamine were purchased from Aldrich. Dichlorotriphenylphosphine (95 %
purity, Aldrich) was stored and manipulated in a dry box. NMR spectra were obtained
either on a Bruker AC-250 (lH, 3,P) or AC-400 (lH, 31P) spectrometer. All 31P NMR
spectra were externally referenced against 85 % H3PO4 . Gas chromatography was
performed on a Hewlett Packard 5971A instrument with a crosslinked capillary column
(10m x 0.53mm, 2.0 urn film thickness) and the following temperature programming:
Tinitiai 40 °C for 2 minutes then 35 °C/min. up to Tr,nai 270 °C. Preparative HPLC was
carried out on a Waters 15-pm Deltapak C4 column (25 x 100 cm) using a mobile phase
of acetonitrile (10 %, v/v, 0.05 M aqueous triethylammonium acetate) and 0.1 M
ammonium acetate buffer and a gradient of 50-100 % of the organic phase over 1 hour.
Mass spectrometry (FABMS) was performed at Louisiana State University and
University of Nebraska-Lincoln Mass Spectrometry facilities. Elemental analyses were
performed by MHW Laboratories (Phoenix, AZ).
2.4.2 General Procedure
At room temperature, a solution of dichlorotriphenylphosphorane (60 mg, 0.18
mmol) in dichloromethane (0.28 mL) was added to a solution of the H-phosphinate
amino acid ester 4 (0.15 mmol) in CH2CI2 (0.7 mL) and pyridine (0.023 mL, 0.29 mmol).
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After 30 minutes, diisopropylethylamine (0.22 mmol) was added to the reaction mixture
followed, after 15 minutes, by the addition of the nucleophile (0.29 mmol for amines,
0.22 mmol for alcohols) in one portion. After an additional 15 minutes, elemental sulfur
(5 mg, 0.15 mmol) or anhydrous t-butyl peroxide (5.5 M in decane, 0.04 mL, 0.22 mmol)
was added. About 30 minutes later the reaction mixture was concentrated, and the
resulting residue was triturated with ethyl acetate ( 3 x 2 mL). The combined ethyl acetate
fractions were washed with NaHCC>3 ( 2 x 3 mL) and brine (6 mL), dried with Na2SC>4,
and then evaporated to give an oily residue.

The compounds were isolated using

reversed-phase HPLC (except were noted) and characterized by 31P NMR, lH NMR, and
FABMS.
2.4.3 Synthesis and Characterization of 1-Amino-1-CyclohexyImethanephosphonous acid
The following compounds were obtained and used in the preparation of
compound 29.
AKdiphenylmethyl) ammonium phosphonite (2 7 )228
Anhydrous hypophosphorus acid (5.94 g, 90 mmol) was dissolved in ethanol (225
mL). Benzhydrylamine (15.5 mL, 90 mmol) was then added to the reaction flask and
stirred for 30 minutes. The solvent was removed with rotary evaporation, and the white
phosphonite crystals were dried under high vacuum. Yield: 22 g (98%). 3IPNMR(101
MHz, EtOH) 1.06 ppm.
1-benzhydryiamino-l-cyclohexylmethanephosphonous acid (28)
The phosphonite salt 27 (4.95 g, 19.79 mmol) and cylcohexane carboaldehyde
(2.40 mL, 19.79 mmol) were dissolved in absolute ethanol, and the reaction mixture was
heated at reflux for 4 hours. A precipitate of the diphenylmethylaminophosphonous acid
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formed upon cooling of the solution. The precipitate was collected by filtration, washed
with ethanol and ether, and dried under high vacuum. Yield: 3.73 g (55%). 3lP NMR
(101 MHz, DMSO) 27 ppm.
l-amino-l-cyclohexylmethanephosphonous acid (29)
An excess of 48% HBr (19 mL) was added to a flask containing the phosphonous
acid 28 (3.73 g, 10.89 mmol). The mixture was refluxed for 1 hour and 30 minutes. The
reaction solution was allowed to cool and then taken up in water (30 mL) and washed
with ether (3 x 10 mL). Rotary evaporation removed the water, and the resulting solid
was dissolved in methanol (60 mL). Then propylene oxide was added until precipitation
started. The white precipitate was collected by filtration, washed with ethanol and ether,
and then dried under high vacuum. Yield: 1.17 g (61%). lH NMR (250 MHz, D2O) 1.35
(m, 11H, c-CfiHu), 2.98 (m, 1H, CH), 7.15 (d, Jph = 525 Hz, 1H, PH) ; 3lP NMR(101
MHz, D2O) 18 ppm. FABMS (glycerol) m/e 178.2 (M + H)+; C, 47.46; H, 9.01; N, 7.90;
found C, 47.65; H, 8.81; N, 7.91.
2.4.4 Synthesis and Characterization of Protected 1-Amino-1Cydohexylmethanephosphonous acids
l-[A-(benzyloxycarbonyI)amino]-l cyclohexylmethanephosphonous acid (30)
The phosphonous acid 29 (0.567 g, 3.20 mmol) was taken up in H2O (8 mL). The
acid dissolved after the pH was adjusted to about 9.5 with 4N NaOH. Then a solution of
N-(benzyIoxycarbonyloxy)succimide (0.867 g, 3.52 mmol) in dioxane (4 mL) was added
over a period of 15 minutes. The pH was periodically checked and adjusted to 9.5. After
stirring at room temperature for six hours, the reaction mixture was extracted with ether
( 2 x 6 mL). 6 N HC1 (12 mL) was added to the aqueous phase. The white precipitate
was collected by filtration and was dried under high vaccum. Yield: 0.769 g (77%). lH
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NMR (250 MHz, CD3OD) 1.35 (m, 11H, c-QsHn), 3.45 (m, 1H, CH), 5.05 (s, 2H,
PhCH2>, 5.38 (br s, 1H, NH), 7.12 (d, Jra = 575 Hz, 1H, PH) ) 7.33 (m, 5H, Ph); 3lP
NMR (101 MHz, CD3OD) 30 ppm. FABMS (glycerol) m/e 311.7 (M + H)+; C, 58.01;
H, 6.70; N, 4.50; found C, 57.81; H, 6.61; N, 4.55.
l-[A-(2-nitrobenzenesulfonyI)amino]-l cyclohexylmetbanephosphonous ad d (31)
The phosphonous add 29 (0.682 g, 3.85 mmol) was taken up in H2O (10 mL).
The add dissolved after the pH was adjusted to about 9.5 with 4N NaOH. This solution
was brought to 4 °C , and then a solution of 2-nitrobenzenesulfonyl chloride ( 0.939 g,
4.24 mmol) in dioxane ( 4 mL) was added over a period of 15 minutes. The pH was
periodically checked and adjusted to 9.5. After stirring at 4 °C for six hours, the reaction
mixture was allowed to warm to room temperature. It was extracted with ether ( 2 x 6
mL).

6

N HC1 (14 mL) was added to the aqueous phase. The white precipitate was

colleded by nitration and was dried under high vaccum. Yield: 1.07 g (94%). *H NMR
(250 MHz, DMSO) 1.53 (m, 11H, c-QHn), 3.25 (m, 1H, CH), 4.85 (d, Jra = 525 Hz,
1H, PH), 8.12 (m, 4H, Ph), 8.56 (d, 1H, NH), 3lP NMR (101 MHz, DMSO) 30 ppm.
FABMS (3-NBA) m/e 363.0 (M + H)+; C, 43.11; H, 5.25; N, 7.73; found C, 42.90; H,
5.50; N, 7.69.
l-[iV-(4,4-dimethyl-2,6-dioxocyclohexylidene ethyl) amino]-lcyclohexylmethanephosphonous ad d (32)
The phosphonous add 29 (0.823 g, 4.65 mmol) was placed in a flask equipped
with a condenser, heating mantle, and an argon inlet Dry CH2CI2 (12 mL) was added to
the reaction vessel and stirred vigorously. TMS-C1 (1.18 mL, 9.31 mmol) was added in
one portion. The mixture was refluxed for 2 hours and then cooled in an ice bath. DIEA
(1.45 mL, 837 mL) and 2-acetyldimedone (0.564 g, 3.10 mmol) were added in
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succession. The reaction mixture was stirred with cooling for 20 minutes and then
warmed to room temperature for 2 hours. The reaction mixture was concentrated and
then distributed between Et2 0 (25 mL) and 2.5% NaHC03 (50 mL). The aqueous layer
was extracted with 2 x 20 mL of Et2 0 . The aqueous layer was then acidified to pH 2
with 1 N HC1 and extracted with 3 x 15 mL of EtOAc. The combined aqueous layers
were then dried over Na2S0 4 , filtered, concentrated, and dried in vacuo. Appropriate
solvents were used to recrystallized the final product. Yield after recrystallization:
0.40 g (37%). *H NMR (250 MHz, DMSO) 0.98 (s, 6 H, (CHsh) 1.53 (m, 11H, c-QsHn),
2.25 (s, 3H, CH3), 2.50 (s, 4H, 2 CH2) 4.15 (m, 1H, CH), 7.00 (d, JPH= 500 Hz, IH, PH),
13.5 (d, 1H, NH), 3lP NMR (101 MHz, DMSO) 24 ppm. FABMS (3-NBA) m/e 342.1
(M + H)+‘» C, 59.80; H, 8.21; N, 4.10; found C, 59.73; H, 8.37; N, 3.99.
2.4.5 Synthesis and Characterization of Protected 1-Amino-l-CyclohexylmethaneH-Phosphinate Esters
l-[7V-(benzyIoxycarbonyl)amino]-l-cyclohexylmethanephosphonous acid,
p-nitro benzyl ester [Cbz-CyhGly y [POH(OpNb)] (4)
According to the procedure described by Sampson and Bartlett, EDC (0.698 g,
3.64 mmol) was added to a solution of the Cbz-protected phosphonous acid 30 (0.566 g,
1.82 mmol) and para-nitrobenzyl alcohol (0.279 g, 1.82 mmol) in anhydrous CH2CI2 (10
mL). After stirring at room temperature for 10 hours, the solution was diluted with
EtOAc (100 mL), washed with saturated KH2PO4 (2 x 50 mL) , saturated NaHC0 3 (50
mL), and brine (50 mL), dried over Na2S0 4 , filtered, and evaporated to dryness. A white
powder was obtained. Yield: 0.67 g (82%). lH NMR (250 MHz, CDC13) 1.38 (m, 11H,
c-CeHn), 3.92 (m, 1H, CH-P), 5.10 (s, 2H, CH2OOC), 5.42 (d, 2H, CH2OP), 5.44 (br s,
IH, NH), 7.12 (d, JPH = 560 Hz, IH, P-H), 7.33 (m, 5H, Ph), 7.89 (d, 2H, Ph-N02), 8.18
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(d, 2H, Ph-N02); 3,P NMR (101 MHz, CDC13) 36.1 and 37.1 ppm (1:1.1); FABMS
(NBA) m/e 447.8 (M + H)+; C, 59.22; H, 5.83; N, 6.27; found C, 59.36; H, 5.89; N, 6.15.
l-[iV-(2-nitrobenzenesuIfonyl)amino]-l cyclohexylmethanephosphonous acid,
p-nitro benzyl ester (2 1 )
To a solution of the NBS-protected phosphonous acid 31 (0.615 g, 1.70 mmol)
and para-nitrobenzyl alcohol (0.260 g, 1.70 mmol) was added EDC (0.487 g, 2.54 mmol)
in anhydrous CH2CI2 (10 mL). After stirring at room temperature for 10 hours, the
solution was diluted with EtOAc (100 mL), washed with saturated KH2P 0 4 (2 x 50 mL),
saturated NaHC0 3 (50 mL), and brine (50 mL), dried over Na2S04, filtered, and
evaporated to dryness. A white powder was obtained. Yield: 0.67 g (94%). lH NMR
(250 MHz, CDCI3) 1.55 (m, 11H, c-Q H u), 3.85 (m, IH, CH-P), 5.20 (m, 2H, CH2OP),
5.35 (d, JPH= 510 Hz, IH, P-H), 7.85 (d, 2H, Ph-N02), 8.20 (m, 4H, PhS02) 8.35 (d, 2H,
Ph-N02) 8.62 (s, IH, NH); 31P NMR (101 MHz, CDC13) 35.5 and 36.5 ppm; FABMS (3NBA) m/e 498.1 (M + H)+; C, 48.30; H, 4.83; N, 8.50; found C, 48.44; H, 5.00; N, 8.57.
l-[iV-(4,4-dimethyl-2,6-dioxocycIohexylidene ethyl) amino]-lcyclohexylmethanephosphonous acid, para-nitrobenzyl ester (2 2 )
To a solution of the Dde-protected phosphonous acid 32 (0.133 g, 0.389 mmol)
and para-nitrobenzyl alcohol (0.0596 g, 0.389 mmol) was added EDC (0.170 g, 0.887
mmol) in anhydrous CH2CI2 (5 mL). After stirring at room temperature for 10 hours, the
solution was diluted with ethyl acetate (50 mL), washed with saturated KH2P0 4 (2 x 25
mL), saturated sodium bicarbonate (25mL), and brine (25 mL), dried over Na2S04,
filtered, and evaporated to dryness. A white powder was obtained. Yield: 0.11 g (57%).
'H NMR (250 MHz, DMSO) 1.1 (s, 6 H, (CHsh) 1.50 (m, 11H, c -C ^ n ), 2.35 (s, 3H,
CH3), 2.62 (s, 4H, 2CH2) 4.15 (m, IH, CH), 5.25 (m, 2H, CH2Ph), 7.15 (d, Jph = 530 Hz,
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1H, PH), 7.8 (d, 2H, PhN02), 8.44 (d, 2H, PhN02), 14.1 (br s, IH, NH), 3lP NMR (101
MHz, DMSO) 32.9, 34.4 ppm. FABMS (3-NBA) m/e 477.1 (M + H)+; C, 60.51; H,
6.93; N, 5.88; found C, 60.69; H, 7.05; N, 5.86.
2.4.6 Preparation of Oxazaphospholine 7 using PS-DIEA Resin
In a glovebox, the phosphonochloridite 3 (0.05 g, 0.11 mmol) in CH2CI2 (0.5 mL)
was added to a suspension of PS-DIEA resin (3.68 mmol/g (loading), 0.06 g, 0.21 mmol)
in dichloromethane. The reaction mixture stirred at room temperature for 30 minutes.
Then the resin was filtered and washed with anhydrous CH2CI2 (3 x 0.2 mL). Major 3lP
NMR (101 MHz, CH2CI2) peaks of filtrate; 180 ppm (proposed oxazaphospholine 7), 27
ppm (triphenylphosphine oxide). No signal was detected on the solid support by gel 3>P
NMR.
2.4.7 Synthesis and Characterization of Complex Phosphonamide and
Thiophosphonamide Dipeptides
Cbz-CyhGly y [P (O) (OPNB) NH] Trp-NH2 (la)
It was prepared according to the general procedure. Yield: (18%). lH NMR (250
MHz, CD3CN) 1.5 (m, 11H, c-QHu), 3.2 (m, 2H, CH2-indole), 4.0 (m, IH, CH-P), 4.5
(m, IH, CHCONH2), 5.1 (m, 4H, CH2OOC + CH 2OP), 5.7 (m, 3H, NHP + NH2), 6.5 (br
d, IH, NHCO), 7.2 (m, 4H, indole), 7.4 (d, IH, vinylic), 7.6 (m, 5H, O f t ) , 7.7 (d, 2H,
Ph), 8.2 (d, 2H, Ph) 9.2 (br s, IH, NH-indole); 3lP NMR (101 MHz, CD3CN) 28 and 29
ppm. FABMS (3-NBA) m/e 648.2 (M + H)+.
Cbz-CyhGly y [P (S) (OPNB) NH] Trp-NH2 (lb)
It was prepared according to the general procedure. Yield: (14%) lH NMR (250
MHz, CD3CN) 1.5 (m, 11H, c-CsHu), 3.2 (m, 2H, CH2-indole), 4.0 (m, IH, CH-P), 4.5
(m, IH, CHCONH2), 5.1 (m, 4H, CH2OOC + CH 2OP), 6.0 (m, 3H, NHP + NH2), 6.5 (br
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d, 1H, NHCO), 7.1 (m, 4H, indole), 7.3 (d, IH, vinylic), 7.5 (m, 5H, QHs), 7.7 (d, 2H,
Ph), 8.1 (d, 2H, Ph) 9.2 (br s, IH, NH-indole); 3lP NMR (101 MHz, CD3CN) 28 and 29
ppm. FABMS (3-NBA) m/e 664.1 (M + H)+.
Cbz-CyhGly y (P (O) (OPNB) NH] Trp-OMe (lc)
It was prepared according to the general procedure. Yield: (15%) lH NMR (250
MHz, CD3CN) 1.5 (m, 11H, c-CeH,,). 3.3 (m, 2H, CH2-indoIe), 3.5 (s, 3H, OCH3), 3.7
(m, IH, CH-P), 4.3 (m, 2H,

CHCOOCH3 + PNH), 4.9 (m, 4H, CH2OOC + CH2OP), 5.8

(dd, IH, NHOC), 7.0 (m, 4H, indole), 7.2 (d, IH, vinylic), 7.5 (m, 5H, QsHs), 7.7 (d, 2H,
Ph), 8.1 (d, 2H, Ph) 9.3 (br s, IH, NH-indole); 3,P NMR (101 MHz, CD3CN) 28 and 29
ppm. FABMS (3-NBA) m/e 663.2 (M + H )\
Cbz-CyhGly y [P (S) (OPNB) NH] Trp-OMe (Id)
It was prepared according to the general procedure. Yield: (30%) ‘H NMR (250
MHz, CD3CN) 1.5 (m, 11H, c-CeHn), 3.2 (m, 2H, CH2-indole), 3.6 (s, 3H, OCH3), 4.1
(m, IH, CH-P), 4.4 (m, 2H, CHCOOCH3 + PNH), 4.9 (m, 4H, CH2OOC + CH2OP), 5.7
(dd, IH, NHCO), 7.2 (m, 4H, indole), 7.4 (d, IH, vinylic), 7.6 (m, 5H, CsHs), 7.7 (d, 2H,
Ph), 8.2 (d, 2H, Ph) 9.2 (br s, IH, NH-indole); 31P NMR (101 MHz, CD3CN) 28 and 29
ppm. FABMS (3-NBA) m/e 678.2 (M + H)+.
Synthesis of Cbz-CyhGly y [P (S) (OPNB) NH] Trp-OMe (Id) using PS-PhjPCU
In a glovebox, the H-phosphinate ester 4 (0.05 g, 0.11 mmol) in CH2C12 (lmL)
and pyridine (4 pL, 0.06 mmol) was added to the PS-Pti3PCl2 resin (1.24 mmol/g, 0.2 g,
0.176 mmol, Argonaut Technologies), which was suspended in CH2C12 (~

1

mL). The

reaction mixture was periodically stirred for 1.5 hours, and then the activated species was
filtered from the resin. 31P NMR (101 MHz, CT^Cl^ of activated species: 195 ppm.
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Under argon, a solution of D-tryptophan methyl ester (0.04 g, 0.16 mmol) in CH2CI2 (0.5
mL) was added dropwise over 15 minutes to the activated species. After 30 minutes, a
31P NMR spectrum was taken. The coupling peaks resonated around 135 and 137 ppm.
To the resulting phosphonamidites was added elemental sulfur (3 mg, 0.11 mmol). The
sulfurized species resonated around 81 ppm. FABMS (NBA) m/e 541.2 (Desired masspNb).
2.4.8 Synthesis and Characterization of Thiophosphonamides, Phosphonamides,
and Thiophosphonates
Cbz-CyhGly y [P (S) (OPNB) NH] Leu-OMe (12)
It was prepared according to the general procedure (0.23 mmol scale) and purified
by pressure alumina chromatography using EtOAc-Hexane (1:1) as the eluent. Yield: 39
mg (28%). ‘HNMR (250 MHz, CD3CN) 0.88 (d, 6 H, (CH3)2), 1.20 (m, IH, CH(CH3)2),
1.73 (m, 11H, c-QsHu), 3.18 (m, 2H, CH2), 3.62 (s, 3H, OCH3), 4.14 (m, IH, CH-P), 4.4
(m, IH, CHCOOCH3 + PNH), 5.02 (m, 4H, CH2OOC + CH2OP), 5.87 (d, IH, NHCO),
7.36 (m, 5H, CeHs), 7.57 (d, 2H, Ph), 8.22 (d, 2H, Ph); 31P NMR (101 MHz, CD3CN)
86.9 and 88.3 ppm. FABMS (3-NBA) m/e 606.3 (M + H)+.
Cbz-CyhGly y [P (S) (OPNB) NH] Gly-OEt (13)
It was prepared according to the general procedure (0.14 mmol scale). Yield: 20
mg (26%). lH NMR (250 MHz, CD3CN) 0.95 (d, 3H, CH3), 1.65 (m, 1IH, c-OH,,), 2.75
(m, 2H, CH2), 3.98 (m, IH, CH-P), 4.23 (q, 2H, OCH 2CH3), 5.02 (m, 3H, CH2OOC +
PNH), 5.52 (s, 2H, OCH2Ph), 5.89 (d, IH, NHCO), 7.36 (m, 5H, CsHs), 7.50 (d, 2H, Ph),
8.15 (d, 2H, Ph); 3,P NMR (101 MHz, CDsCN) 89.7 ppm. FABMS (3-NBA + Li) m/e
570.2 (M + Li)+.
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Cbz-CyhGly y [P (O) (OPNB) NH] Gly-OEt (14)
It was prepared according to the general procedure (0.14 mmol scale). Yield: 16
mg

(21%). ‘H NMR (250 MHz, CD3CN) 0.95 (d, 3H, CH3), 1.66 (m, UH, c-CeHu),

2.75 (m, 2H, CH2), 3.95 (m, 1H, CH-P), 4.20 (q, 2H, OCH2CH3), 5.00 (m, 3H, CH2OOC
+ PNH), 5.52 (s, 2H, OCH2Ph), 5.87 (d, IH, NHCO), 7.36 (m, 5H, CeHs), 7.50 (d, 2H,
Ph), 8.15 (d, 2H, Ph); 3lP NMR (101 MHz, CD3CN) 39.2 ppm. FABMS (3-NBA + Li)
m/e 554.2 (M + Li)+.
Cbz-CyhGly y [P (S) (OpNb) (OBn)] (19)
It was prepared according to the general procedure (0.22 mmol scale) and purified
by flash chromatography (silica) using EtOAc-Hexane (1:5) as the eluent. Yield: 19 mg
(15%). lH NMR (250 MHz, CDC13) 1.55 (m, 11H, c-CftH,,), 4.25 (m, IH, CH-P), 5.12
(m, 7H, 3CH2 + NH), 7.35 (m, 10H, 2 0 ^ ) , 7.50 (d, 2H, Ph), 8.18 (d, 2H, Ph); 3IP NMR
(101 MHz, CDC13) 95.1 ppm. HRMS (ESI/FTMS (CH2C12)) m/e 569.1862 (M + H)+.
Cbz-CyhGly y [P (S) (OPNB) O] Ala-OMe (20)
It was prepared according to the general procedure (0.11 mmol scale). Yield: 19
mg

(30%). lH NMR (250 MHz, CD3CN) 1.53 (m, 1IH, c-Q H ,,), 2.85 (m, 3H, CH3),

4.26 (m, IH, CH-P), 5.28 (m, 5H, 2CH2 + PNH), 5.89 (dd, IH, NHCO), 7.36 (m, 5H,
CfiHs), 7.45 (d, 2H, Ph), 8.15 (d, 2H, Ph); 3lP NMR (101 MHz, CD3CN) 96.4,97.3 ppm.
FABMS (3-NBA) m/e 565.2 (M + H)+.
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Chapter 3
Synthesis of a,a-DialkyIated Amino Acid-Rich Peptides
with Antimicrobial Activity
3.1 Introduction
The classical a-helix and the 3to-helix are the two most prevalent helices found in
proteins.3' 1*3 3 Whereas the a-helix is characterized by 3.6 residues per turn and a (i, i +
4), thirteen-membered, hydrogen-bonding pattern, the 3io-helix is distinguished by 3
residues per turn and a (i, i + 3), ten-membered, hydrogen-bonding configuration. The
conformational parameters of the two helices are not widely different; however, the

310 -

helix is slightly tighter and more elongated than the a-helix.3' 1*3 2 The 3io-helix is less
common than the a-helix; it accounts for approximately

10

% of all helical structures

found in proteins.3 3 *3 3 Nevertheless, structural work conducted on the 3io-heIix suggests
that it plays a very important biochemical role.3 3 It is considered to be a protein folding
intermediate to the a-helical conformation.3 4 3 6 Furthermore, it is believed that protein
recognition steps could possibly involve facile transitions between a- and

310 -

helices.34,3'7 Therefore, there has been an enormous interest in trying to understand the
preferences for a- or 3to-helical conformations and the transitions between these two
states.3-2*3 3 -3'8*3' 10
It is well-established that a-aminoisobutyric acid (Aib), as well as several other a,
a-dialkylated amino acids, are strong promoters of the 3io-/a-helical conformation.3 8*3 11
The backbone torsional angles (<|>, \p) (Figure 3.1) of an Aib residue are severely
restricted, resulting in the pronounced propensity of this residue to favor helical
structures, even in short peptides.3'8*3 12 Some proteinogenic amino acids, like leucine
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and alanine, also promote helicity but not to the extent required for preparation of short
3io- or a-helical peptides.3' 10

Allowable phi, psi angle pair for Aib (R. R | = CH-0
-57 °C, -47 °C (right-handed a - or 3io-helix)
57, °C, 47 °C Qeft-handed a - or 3I0-helix)
Figure 3.1 Backbone torsional angles of an Aib residue
The type of helix that an Aib-rich peptide preferentially forms is governed by several
factors such as main-chain length, Aib content, sequence, and environmental conditions.
Karle et. al reported that Aib-rich peptides with 5 residues or less give rise to 3io-helices,
but peptides with ten or more residues form a-heiices.3"12 For medium length peptides (6 10), either an a- or 3io- helix can form, depending mainly on the percentage of Aib’s or
a,a-amino acids (aaAAs) contained in a peptide. Six residue or longer peptides with 50
% or more aaAAs are reported to form a 3io-helix while those containing less than 50%
generally favor an a-helix.3'9 3 ' 12 Basu et al. reported that the location of monosubstituted
amino acids in Aib-rich peptides also affected the 3t</a-helix equilibrium: the a-helix is
favored when two monosubstituted amino acids are next to each other, but the 3to-helix,
when no two monosubstituted amino acids are next to each other.3 9 As far as solvent
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effects, several studies (theoretical and empirical) revealed that Aib-rich peptides favor
the a-helix in polar media but the 3io-helix in nonpolar media.3"3"5 6,3' 13' 3' 14
Until recently, most studies conducted on the solvent effects on the 3io-/a-helix
equilibrium were limited to spectroscopic measurements of hydrophobic peptides (e.g.,
oligomers of Aib) in organic solvents or X-ray structure determinations of peptides
crystallized from organic solvents.3 3 3 '8 3 ' 103' 13' 3' 15 Toniolo et al. reported the first short
(7-mer) Aib-rich peptide that exhibited its 3i®-helical structure in pure water (Figure 3.2).
The peptide comprised the extremely water-solubilizing, azacrown-functionalized aamino acid, L-2-amino-3[l-(l,4,7-triazacyclo-nonane)]propanoic add (ATANP) .3 1316 In
addition, the design and synthesis of short, amphipathic a- and 3io-helices, incorporating
60% Aib content and the water-solubilizing a,a-disubstituted amino acid, Api (4aminopiperidine-4-carboxylic add), that exhibited their designed structures (Figure 3.2)
in aqueous media (25 mM SDS) were reported by Yokum et a / . 3 17 They also reported
that amphipathic design was foremost in controlling secondary structure (helical
preference), overriding traditional key factors such as the number of aaAAs and the order
of the a-amino acids and aaAAs in a sequence. Furthermore, the peptides exihibited
substantial antibacterial activity.3,18
An amphipathic helix is a protein helix that has opposing polar and non-polar
faces oriented along its axis.3' 19 Scores of naturally occurring antimicrobial peptides
contain an amphipathic a-helix as the primary structural motif.330'331 They kill bacteria
by primarily disrupting the cell membrane. Many studies directed toward understanding
the structure-activity relationships (SAR) of natural antimicrobial peptides indicate that
their amphipathic character plays a vital role in their biological activities (peptide
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membrane interactions). 3. 20- 3.21 Also, a reported, general trend exists between the helicity
of an amphipathic peptide and bioactivity. Generally, the higher a peptide's helicity is,
the higher its bioactivity. However, amphipathic, a-helical peptides with 18 or more
residues tend to have high cytotoxicity.

Short peptides (10-16 residues of varying

sequences) containing the amphiphathic a-helix as a consistent structural feature were

H

Ac-Aib-ATANP-Aib-Aib-ATANP-Aib-Aib-OCH3

m .

NH,
H
H-Api-Aib-Aib-Lys-Aib-Aib-Lys-Aib-Aib-Api-NH2
Figure 3.2 Short, water-soluble 3io-helical peptides. The top peptide has 3io-helicity in
pure water and the bottom peptide (Ipi-10), in aqueous 25 mM SDS.
shown to have comparable antimicrobial activities as longer or native peptides. They
have also exhibited a higher degree of selectivity of bacterial killing over lysis of red
blood cells.3"20' 3^ 2

Conversely, many natural peptide antibiotics, especially those

containing Aib residues, are thought to form 3io-helices.3 23*3 J5 In addition to reports of
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short, amphipathic a-helical peptides with significant antimicrobial activity, there has
also been a report of short, amphipathic, 3io-helical peptides exhibiting antibacterial
activity.3'25 Since 3io-helical peptides are about 20% longer than a-helical peptides with
the same number of residues, amphipathic 3io-helical peptides could possibly retain
biological activity at shorter peptide lengths than analogous a-helical peptides.
In our work we were interested in the design and efficient synthesis of short,
amphipathic 3io-helical peptides (Aib-rich) that are capable of exhibiting good
antimicrobial activity and low cytotoxicity. The general strategy was to shorten the
amphipathic 10-mer (Ipi-10) in Figure 3.2 to a 9-mer by removing the /'/-terminal Api
residue. We proposed that removal of this residue would increase the 3io-helicity-and
therefore bioactivity-of the resulting 9-mer in an aqueous medium due to the removal of
electrostatic repulsive interactions that may exist between the N-terminus amine and
charged Api-residue. We observed that the 7-mer peptide (Figure 3.2), which folded into
a 3 io-helix in pure water,3' u

' 16

had shorter a-amino acid side-chains than the 10-mer

peptide. Therefore, we decided to expand the scope of our research by investigating the
effects of further shortening of the length (methylene groups) of the lysine residues in our
9-mer peptide. We also envisioned an increased 3io-helicity trend with decreased sidechain length in our designed peptides. Furthermore, we were interested in the solvent
(aqueous-organic) effects on the 3io-/a-helix equilibrium on our designed, amphipathic
3io-helical peptides.
Electronic circular dichroism (CD) is the most widely employed spectroscopic
technique for monitoring the secondary structure of peptides and proteins as a function of
solvent.* 27 Both 3io-and a-helical peptides give rise to negative CD bands around 222

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

76
nm (n-wi*) and 207 nm (it->7c* ) .3'23 A positive band around 191 nm (tc-mi*) is also
characteristic of both types of helical peptides, although it is usually much weaker in 3io
helical peptides.

The ratio R of the intensity of the negative bands, where R =

[0]n-*«/[9]*-Mi*> is a generally accepted parameter used to distinguish a 3to-helix from an
a-helix. For an a-helix R = 1, but for a 3io helix R = < O.4.3 22
3.2 Results and Discussion
32.1 Peptide Design and Synthesis
The four homologous series of short peptides (9-mers) 3.1-3.4 and their acetylated
versions 3.5-3.8 listed in Table 3.1 are die novo designed peptides composed of 78% a,adisubstituted amino acids (aaAAs).

The sequences of 3.1-3.8 were based on one of the

peptides (3.9) first described by Yokum et al,317 Peptide 3.1 is actually 3.9 minus the Nterminal Api (4-aminopiperidine-4-carboxylic acid) residue. Like 3.9, peptides 3.1-3.8
were designed to form amphipathic, 3io-helical peptides. The 9-mers 3.1-3.8 contain
either two lysines or two lysine analogs-omithine, 2 ,4 diaminobutanoic acid (Dab), or 2,
3 diaminopropanoic acid (Dap)-and 7 achiral aaAAs-six Aib residues and one Api
residue. The distinction between each peptide, besides acetylation, is the length (# of
methylene groups) of the side-chains of its a-amino acids (Figure 3.3). In this study we
primarily investigated, starting with 3.1, how further shortening (main-chain and sidechain) of 3.9 would affect the resulting peptide’s secondary structure in various solvent
media, antimicrobial activity, and cytotoxicity.

Furthermore, we hypothesized that

removal of the positive charge (- Api) at the N-terminus of 3.9 would increase the
designed amphipathic, 3io-heIicity of the resulting peptide in aqueous media, thereby,
possibly improving bioactivity due to an overall better peptide-membrane interaction.
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Table 3.1 Sequences of peptides 3.1-3.10
Peptide#, Name________________________________ Sequence
3.1

Ipi-9

H-Aib-Aib-Lys-Aib-Aib-Lys-Aib-Aib-Api-NH2

3.2

Ipiom-9

H-Aib-Aib-Om-Aib-Aib-Om-Aib-Aib-Api-NH2

3.3

Ipidab-9

H-Aib-Aib-Dab-Aib-Aib-Dab-Aib-Aib-Api-NH2

3.4

Ipidap-9

H-Aib-Aib-Dap-Aib-Aib-Dap-Aib-Aib-Api-NH2

3.5

AcIpi-9

Ac-Aib-Aib-Lys-Aib-Aib-Lys-Aib-Aib-Api-NH2

3.6

AcIpiom-9

Ac-Aib-Aib-0 m-Aib-Aib-0 m-Aib-Aib-Api-NH2

3.7

AcIpidab-9

Ac-Aib-Aib-Dab-Aib-Aib-Dab-Aib-Aib-Api-NH2

3.8

AcIpidap-9

Ac-Aib-Aib-Dap-Aib-Aib-Dap-Aib-Aib-Api-NH2

3.9

Ipi- 1 0

3.10

Aclpi-10

H-Api-Aib-Aib-Lys-Aib-Aib-Lys-Aib-Aib-Api-NH2
Ac-Api-Aib-Aib-Lys-Aib-Aib-Lys-Aib-Aib-Api-NH2

The aaAAs were incorporated into 3.1-3.8 to induce a stable, helical, secondary
structure in the short peptides. The L-lysine or L-lysine-like residues were included to
induce a right-handed helix (detectable by CD) and were separated well in the middle of
the sequences (in 4th and 7th position) to have the greatest effect. 3 9 As mentioned above
the peptides were designed to be amphipathic with the charged Api and lysine or lysine
like residues forming the hydrophilic face and the nonpolar Aib residues forming the
hydrophobic face. As seen in Figure 3.4 the designed peptides are more amphipathic in
the 3to-helical representation.
The % 3 io-helix was estimated using the following equation: % 3 io-helix = (100)
[[01*-rt*/ -21,500], where the minimum for [S]*-** is observed from 205-209 nm.317,3'28
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RHN,
NH2
NH
R-Aib-Aib-Xxx-Aib-Aib-Xxx-Aib-Aib-Api-NH2
Xxx = Lys (n = 4), Om (n = 3), Dab (n = 2), or Dap (n = 1) R = H, Ac, Api, Ac-Api
Figure 3 3 General chemical structure of peptides 3.1*3.10
The CD spectra of H-(Leu-Arg-Leu)g-OH in diphosphatidylcholine liposomes served as
the model 3io-helix, where

= -21,500 deg cm2 dmol' 1 is defined as 100%

3 jo -

helix.3-28 No formal methods have been suggested in literature for the estimation of %
3io-helicity. For estimation of the % a-helix the following equation was employed: % ahelix = -100 ([0]n-*« + 3000) / 33,000, where the minimum for the [0]n_,*» is observed
from 222-225 nm.3'29
Solid-phase synthetic techniques were employed, using a Milligen 9050 peptide
synthesizer, in the prepartion of our designed peptides 3.1-3.8 and peptides 3.10*3.12.
The aaAAs employed in our synthesis were Fmoc-Api(Boc)-OH, Fmoc-Aib-OH, and the
dimer, Fmoc-Aib-Aib-OH (Figure 3.5). The synthesis of peptides containing multiple
aaAAs is inherently complicated due to severe steric hindrance caused by
tetrasubstitution at the a-carbon. Previously, the use of aaAA residues has been limited
because of the difficulty of coupling or harsh conditions used for their incorporation.3 11
Carpino’s development of acid fluorides for aaAA couplings provided the first method
for an efficient, mild synthesis (solution- and solid-phase) of peptides rich in aaAAs.330331

This method was initially employed in the preparation of 3.9 and 3.10,317 upon which

the design of our targets are partially based, with unsatisfactory yields. We therefore
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attempted the preparation of our first peptide 3.1 by using a reported improved in situ
coupling protocol described by Albericio et al.332 In this method the phosphonium-based

5

O /Y v v 1
Art)
a-Helix

o

Aft

©
3

Xxx
3io-HeIix

AphO
Aib

Aib

Aib
Aib

Aib
Aib

R-Aib-Aib-Xxx-Aib-Aib-Xxx-Aib-Aib-Api-NH2
Xxx = Lys, Om, Dab, or Dap

R = H, Ac

Figure 3.4 The a- and 3io-helicaI wheel diagrams and sequence of peptides 3.1- 3.8
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OH
Fmoc
N
Boc
Fmoc-Aib-OH

Fmoc-Api (Boc)-OH

H

O

Fmoc-Aib-Aib-OH
Figure 3.5 The residues employed in synthesis of peptides 3.1-3.10
amino acid (Api, Aib, and Lys),

8

equivalents of DIEA, and a Fmoc-PAL-PEG-PS resin

were employed. However, unsatisfactory yields (2-5%) were also obtained initially with
this method.

From analysis of the Fmoc UV traces, which were used to monitor or

gauge the efficiency of each coupling step, it was determined that every second Aib was
not coupling efficiently. Therefore, in an effort to improve the yield of 3.1, every second
Aib in the sequence was double coupled. Again, no significant improvement in yields
was observed, even with refluxing at 50 °C.
Our next strategy was to employ the Aib residue as a dimer (Fmoc-Aib-Aib-OH).
We reasoned that the use of the dimer could at least eliminate or lessen the formation of
deletion sequences (seen in MALDI of collected HPLC fractions), thus, potentially
improving the yields of 3.1. Conversely, we recognized that the use of an Aib dimer
could possibly impose even more steric hindrance. Nevertheless, we prepared (solutionphase) Fmoc-Aib-Aib-OH for use in preparation of 3.1 and, eventually, the other peptides
listed in Table 3.1.
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The dimer, Fmoc-Aib-Aib-OH, was prepared (Scheme 3.1) by using a
combination of CarpinG’s acid fluoride method33 0"331 and Bolin’s procedure.333 The
monomer, Fmoc-Aib-OH, was first treated with cyanuric fluoride to form the amino acid
fluoride 3. Compound 3 was then reacted with the silylated amino acid 5, which was
prepared from the reaction of H-Aib-OH 4 and trimethylsilylchloride (TMS-C1), to form
the dimer 6 , after recrystallization from chloroform/hexane, in 70% yield.
In the first attempted synthesis of 3.1 employing the Aib dimer and application of
heat (50 °C), we observed, from the Fmoc UV traces, that the first dimer of the sequence
coupled very poorly but the rest of the Aib dimers coupled very well. However, the
overall yield (~ 2%) of 3.1 was still low because of the very inefficient coupling of the
first dimer. We therefore decided to use the Aib monomers, followed by double coupling
after each one, for the first two Aib’s in the sequence but to continue to use the Aib dimer
in the rest of the sequence along with refluxing (50 °C). This modification resulted in a
significant yield increase for 3.1 (20% yield). The dramatic improvement in efficiency of
preparation of 3.1 can be readily observed in the semi-preparatory HPLC chromatograms
presented in Figure 3.6 and Figure 3.7. Also, this method was used to prepare the rest of
the peptides listed in Table 3.1 in yields up to 25%. Analytical HPLC was used to check
the purity of the peptides (e.g., see Figure 3.8, Figure 3.9, Figure 3.10, Figure 3.11,
Figure 3.12, and Figure 3.13,).
The good synthetic results of our target 9-mers and 10-mers (Table 3.1) were
attributed mainly to the incorporation of our Aib dimer. The use of Fmoc-Aib-Aib-OH
lessened the formation of deletion sequences while increasing the yields of the desired
sequences. However, as alluded to above, the Aib dimer wasn’t effective, in terms of
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peptide yield, when used for the first two Aibs in the synthesis of the peptides. This was
attributed to steric factors arising potentially from the coupling of three sequential
aaAAs (Api + Aib dimer) as well as steric bulkiness from the resin. The sequential
coupling of Aibs is generally difficult due to inherent strain caused by the additional
substituent on the a-carbon. Our dimer lessens that complexity significantly because
instead of being involved in sequential Aib couplings, the dimer is actually coupled to an
a-amino acid in each peptide’s sequence.

R nxT

OH

II 1 *

+

**

j
F

pyridine

Si
H £^
O

II

Fmoc" ' X F
/ \

1 .3

^ C1

1DEEA
3. HzO

CHjOz
5

H

O

Rnoc
'

H

O

Scheme 3.1 Synthesis of Fmoc-Aib-Aib-OH 6
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Peptide 3.1

Figure 3.6 Semi-pieparatory HPLC profile of crude containing peptide 3.1 before
improved coupling protocol. HPLC was carried out on a Waters 5 Jim C4 reversed-phase
column ( 8 x 100 mm) using a mobile phase of water (0.05 %, v/v, TFA) and acetonitrile
(0.05 %, v/v, TFA), a gradient of 10-50 % of organic phase over 50 minutes and flow rate
of 1 mL/min. The absorption (UV) was monitored at 222 nm.

Peptide 3.1
E
c
<N
fS

/

CS

4U3

§
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s

X)
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Figure 3.7 Semi-preparatory HPLC profile of crude containing peptide 3.1 after
employing improved coupling protocol. HPLC was carried out on a Waters 5 jun C4
reversed-phase column ( 8 x 100 mm), a gradient of 10-50 % of organic phase over 50
minutes and flow rate of 1 mL/min. The absorption (UV) was monitored at 222 nm.
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Figure 3.8 Analytical HPLC purity check of isolated 3.1. HPLC was carried out on a
Vydac 5-jiM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA)
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40
min. and a flow rate of 1 mL/min.
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Figure 3.9 Analytical HPLC purity check of isolated 3.2. HPLC was carried out on a
Vydac 5-fiM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA)
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40
min. and a flow rate of 1 mL/min.
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Figure 3.10 Analytical HPLC purity check of isolated 3.4. HPLC was carried out on a
Vydac 5-pM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA)
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40
min. and a flow rate of 1 mL/min.
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Figure 3.11 Analytical HPLC purity check of isolated 3.6. HPLC was carried out on a
Vydac 5-pM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA)
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40
min. and a flow rate of 1 mL/min.
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Figure 3.12 Analytical HPLC purity check of isolated 3.9. HPLC was carried out on a
Vydac 5-jiM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA)
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40
min. and a flow rate of 1 mL/min.
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Figure 3.13 Analytical HPLC purity check of isolated 3.10. HPLC was carried out on a
Vydac 5-jiM C-18 column (250 x 4 mm) using a mobile phase of H2O (0.05%, v/v, TFA)
and CH3CN (0.05%, v/v, TFA) with a gradient of 50-100% of the organic phase over 40
min. and a flow rate of 1 mL/min.
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3.2.2 Solvent Effects on 3io-/a>HeIix Equilibrium
Peptides 3.1-3.8 were studied in six different solvent systems: 25 mM SDS,
sodium phosphate buffer (pH = 7), CH3CN-TFE (trifluoroethanol) (9:1), and CH3CNH2O [(9:1), (3:1), and (1:1)]. The designed 3io-helical structure of 3.1 (Ipi-9) was most
evident in 25 mM SDS (Table 3.2). However, since its R value, 0.51, is higher than the
theoretically accepted value, Ipi-9 is most likely a mixture of both 3 10 helices (estimated
23%) and a-helices (estimated 17%). In buffer, Ipi-9 exhibits a more a-helical (R = 0.62,
16%) structure, although weak, than 3 10 helical. Also, for Ipi-9, as the percentage (501 0 0 %)of

organic composition increases in the aqueous/organic mixtures, the percent a-

helicity increases, with the high being 49% in CH3CN-TFE (9:1). This same trend of
increased a-helicity in the 50-100% aqueous/organic mixtures is also observed with 3.2
(Ipiom-9) (Table 3.3). However, in SDS micelles, the CD spectrum (R = 0.86) of Ipiom9 is indicative of an a-helical (13%) structure. The designed 3io-helical structure of
Ipiom-9 is observed most or best in buffer, where its R value is 0.48 and estimated 3iohelicity is 24%. The R values and the estimated percent helicity of both Ipiom-9 and
Ipidab-9 in buffer and 50-75% aqueous/organic mixtures reflect, in general, a significant
population of both 3io- and a-helical conformations (Table 3.4).

Based on the

characteristic minima (n-wt* and ic-mc*) of helices, Ipidap-9 appears to be helical only in
CH3CN-H2O (9:1). In this latter solvent system, Ipidap-9 is a-helical with a R value of
0.72 and 28% helicity. In CH3CN-TFE (9:1), Ipidap-9 appears to be a random coil with a
minimum centered around 197 nm and a maximum around 215 nm.
As stated in the “Peptide Design” section, the construction of Ipi-9 was based on
the 3to-helical design of Ipi-10. Indeed, at low temperatures (0-5 °C) in 25 mM SDS,
Ipi-10 is folded into its designed structure (R = 0.32,25% 3io-helicity) as opposed to Ipi-
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9, which favors an a-helicai structure (R = 0.65, 15% a-helicity) at low temperatures in
SDS micelles. Solutions of SDS micelles, which possess a negatively charged head
group and aliphatic tail, are known for induction of ordered structures in peptides and
proteins. The induction of secondary structure is initiated by the binding of the anionic
surfactant to the cationic side-chain groups of the peptide; this enhances the binding
affinity of the peptides to the hydrophobic interior.3-34 Therefore, the observance of the
designed 3io-helix preferably in Ipi-10 than Ipi-9 may be due to the smaller hydrophilic
face of Ipi-9; the hydrophilic faces of Ipi-9 and Ipi-10 (R = 0.32) are composed of 3
residues and 4 residues, respectively. The larger positively charged face of Ipi-10 (+ 5
overall charge) probably allows for more efficient micelle binding, resulting in better 310 helical stabilization than Ipi-9 (+ 4 overall charge) at low temperatures in 25 mM SDS.
Conversely, at 25 °C in 25 mM SDS, Ipi-10 appears to be a-helical (R = 0.67, 11%)
while the secondary structure of Ipi-9 appears to be leaning more toward 3to-helical (R =
0.51, 23%

3 jo

helicity).

Furthermore, for Ipi-10, the same trend,

3 to

to a-helical

transition as the temperature is increased to 25 °C in SDS, is also seen in the 50-100%
aqueous/organic mixtures (compare Table 3.5 to Table 3.6).
Of the four 3io-helical designed peptides 3.1-3.4, 3.1 (Ipi-9) possesses the most
estimated 3io-helical character in SDS (Figure 3.14). Peptides 3.2-33 are more a-helical
in SDS, which is probably due to incomplete micelle binding. This incomplete binding
may have caused the solvent environment of 33 -3 3 to have greater aqueous solvent
characteristics. An a-helix is generally more energetically favored than a 3l0-helix in an
aqueous environment. This is due to the more favorable interactions of the additional
exposed carbonyls and amides of an a-helix with water.3 3

hi contrast, 3io-helical
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peptides are generally more stable in a non-polar environment, which arises from the
additional hydrogen bond formed as compared to the a-helix.33
Table 3.2 CD data and derived structural parameters for Ipi-9 at 25 °C.
[0 W * *

ro w "

R

% Helicity

25 mM SDS

-5025

-2582

0.51

d

9:1 CH3CN-TFE

-19394

-13410

0.69

49(a)

9:1 CH3CN-H2O

-17720

-11936

0.67

45(a)

3:1 CH3CN-H2O

-7528

-4879

0.64

24(a)

1:1 CH3CN-H2O

-8 8 8

-729

0.82

11

Solvent

(a)

-3491
-2170
0.62
16(a)
Buffer (pH = 7)
“Units for [0] are deg cm2 dmol'1.
6The minimum for the [0]*-*** band is observed in the range from ~ 205-209 nm.
T he minimum for the [0]*_»*« band is observed in the range from ~ 222-225 nm.
^The % a-helix is estimated at 17%, and the % 3io-helix is estimated at 23%.
Table 3 3 CD data and derived structural parameters for Ipiom-9 at 25 °C.
Solvent

ro w

*6

[0 W "

R

% Helicity

25 mM SDS

-1336

-973

0.72

13(a)

9:1 CH3CN-TFE

-12866

-8555

0 .6 6

35(a)

9:1 CH3CN-H2O

-4873

-7696

1.5

32(a)

3:1 CH3CN-H2O

-3407

-1911

0.56

15(a)

1:1 CH3CN-H2O

-2975

-1614

0.54

14(a)

-5111
-2474
Buffer (pH = 7)
0.48
d
“Units for [0] are deg cm2 dmol'1.
^The minimum for the [©]*_**• band is observed in the range from ~ 205-209 nm.
T he minimum for the [0]x-*» band is observed in the range from ~ 222-225 nm.
rfThe % a-helix is estimated at 16%, and the % 3io-helix is estimated at 24%.
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Table 3.4 CD data and derived structural parameters for Ipidab-9 at 25 °C.
Solvent

[0 W W

R

% Helicity

25 mM SDS

-955

-583

0.61

11

9:1 CH3CN-TFE

-3173

-1990

0.62

15(a)

9:1 CH3CN-H2O

-2 0 0 0

-2500

1 .2

16(a)

3:1 CH3CN-H2O

-3363

-2179

0.64

16(a)

1:1 CH3CN-H2O

-4166

-2637

0.63

17(a)

(a)

Buffer (pH = 7)
d
-4115
-2364
0.57
"Units for [0] are deg cm 2 dmol'1.
The minimum for the [0]*-*» band is observed in the range from ~ 205-209 nm.
‘The minimum for the [0]*-** band is observed in the range from ~ 222-225 nm.
‘The % a-helix is estimated at 16%, and the % 3io-helix is estimated at 19%.

Table 3.5 CD data and derived structural parameters for Ipi-10 at 5 °C.
Solvent

[0 W ^ r

Rc

% Helicityc

25 mM SDS

-5316

-1750

0.32

25(310)

9:1 CH3CN-TFE

-9916

-3145

0.33

45(310)

9:1 CH3CN-H2O

-6740

-3605

0.54

e

1:1 CH3CN-H2O

-4204

-3118

0.74

10

% (a)

"Units for [0] are deg cm2 dmoPT
T h e minimum for the [0]x-,** band is observed in the range from ~ 205-209 nm.
cData from reference
‘The minimum for the [0]*_,*« band is observed in the range from ~ 222-225 nm.
‘The % a-helix is estimated at 12%, and the %3to-helix is estimated at 31%.
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Table 3.6 CD data and derived structural parameters for Ipi-10 at 25 °C.
Solvent

fe w * *

[0 W * C

R

-941

-627

0.67

11

9:1 CH3CN-TFE

-14603

-10189

0.70

40(a)

9:1 CH3CN-H2O

-7347

-7163

0.97

30(a)

3:1 CH3CN-H2O

-4770

-3831

0.80

25(a)

1:1 CH3CN-H2O

-1 0 2 0

-1576

1.5

14(a)

25 mM SDS

% Helicity
(a)

Buffer (pH = 7)
-7382
-7190
0.97
31(a)
“Units for [0] are deg cm2 dmol'1.
*The minimum for the [0]*-*** band is observed in the range from ~ 205-209 nm.
T he minimum for the
band is observed in the range from ~ 222-225 nm.
However, Ipiom-9, of the four peptides, exhibited the highest estimated 3iohelicity (24%) in aqueous buffer (Figure 3.15). Therefore, shortening the side-chain of
Ipi-9 to form Ipiom-9 resulted in better 3to-helical stabilization in an aqueous buffer
medium, although this 3 to helical stabilization wasn’t afforded to Ipiom-9 in 25 mM
SDS, which may have been due to a host of factors such as ion pairing of the charged
polar groups with SDS sulfonates or even incomplete micelle binding. Maybe the shorter
side-chains of Ipiom-9 interacted less favorably than the side-chains of Ipi-9 with the
hydrophobic region of the SDS micelles. Further shortening of Ipiom-9 to Ipidab-9
resulted, based on R values, in primarily an a-helix in the 90% organic but a significant
population of both helical forms in the other solvent systems tested; however, the helices
were generally much weaker, based on the absolute ellipticity values, than the helices of
Ipi-9 and Ipiom-9 (Table 3.4 and Figure 3.16). A decrease in absolute ellipticity is often
observed with a decrease in a peptide’s main-chain.323 In this study, a shortening of a
peptide’s side-chain also seems to correlate with a decrease in absolute ellipticity.
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Furthermore, this observed weakening of helicity may be caused by the charged amines
of the shorter side-chains of Ipidab-9 hydrogen-bonding to nearby carbonyls, thereby,
decreasing the stability of the folded structures by weakening the strength of the
intramolecular hydrogen-bonds. Similar kinds of bifurcated hydrogen bonds in proteins
between a helix and water or a side-chain have been reported and analyzed.3' 12
Further shortening of Ipidab-9 to form Ipidap-9 results in further helical
destabilization in all of the solvent systems except CH3CN-H2O (9:1), in which an ahelical (R = 0.72, 28%) structure is observed. Ipidap-9 seems to form a random coil in
CH3CN-TFE (9:1) (Figure 3.17). Ipidap-9 lacks a well-defined structure in the other
solvent systems but is not completely random; a blue shift is observed for the 7t->n*
transition. The observed wavelengths of Ipidap-9’s x-wt* transitions in buffer, CH3CNH2O (1:1), CH3CN-H2O (3:1), and 25 mM SDS were 199 nm, 190 nm, 198 nm, and 195
nm, respectively. However, the n-»x* transitions in those solvent systems were observed
around the wavelength ( 2 2 2 nm) expected in a helical peptide.
The terminally-blocked, 3io-helical peptide (7-mer), described by Toniolo et al.,
had a reported R value of 0.36 in buffer (pH = 7,25 °C). In buffer (pH = 7, 25 °C), Ipi-10
has a R value of 0.97, and Ipiom-9, a R value of 0.48. Therefore, our designed 9-mer,
Ipiom-9, is more 3i©-helical in neutral buffer than Ipi-10 but less 3jo-helicaI than the 7mer peptide. The 7-mer is composed of 71% aaAAs, and Ipiom-9, 78% aaAAs.
Further shortening of the main-chain of Ipiom-9 would still result in a significant
percentage, 75%, of aaAAs. Therefore, the further shortening of the main-chain of
Ipiom-9, along with the amphipathic design tool, could possibly lead to a 3io-helical
structure that is even more comparable to the terminally-blocked 7-mer peptide.
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Figure 3.14 CD spectra of Ipi-9 (•), Ipiom-9 (■), Ipidab-9 (?) and Ipidap-9 (♦) in
25 mM SDS.
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Figure 3.15 CD spectra of Ipi-9 (•), Ipiom-9 (■), Ipidab-9 (y) and Ipidap-9 (4 ) in
neutral, aqueous buffer at 25 °C.
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Figure 3.16 CD spectra of Ipi-9 £ ), Ipiom-9 $ ), Ipidab-9
CH3 CN-H20 (9:1) at 25 °C.
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Figure 3.17 CD spectra of Ipi-9 (•), Ipiom-9 (■), Ipidab-9 (▼) and Ipidap-9 (♦) in
CH3 CN-TFE (9:1) at 25 °C.
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Temperature dependence of the CD spectra of 3.1-3.4 in buffer and of 3.1-3.2 in
25 mM SDS were obtained. CD spectra of each peptide were recorded at temperatures in
10° increments from 30 to 70 °C. In buffer all of the peptides were more a-helical than
3 10-helical at all temperatures tested (Table 3.7, Table 3.8, Table 3.9, and Table 3.10).
Table 3.7 CD data and derived structural parameters for Ipi-9 in buffer (pH = 7) at
30 to 70 °C.
Temperature

ro w * *

[0]n-***fl,C

R

% Helicity

30

-3584

-2775

0.77

18(a)

40

-1475

-1006

0 .6 8

12

50

-2170

-1544

0.71

14(a)

60

-2047

-1149

0.56

13(a)

70
-1923
-1293
0.67
“Units for [0] are deg cm2 dm ol1.
*The minimum for the [0]*_«i* band is observed in the range from 205-209 nm.
T h e minimum for the
band is observed in the range from 222-225 nm.

(a)

13(a)

Table 3.8 CD data and derived structural parameters for Ipiom-9 in buffer (pH = 7) at
30 to 70 °C.
Temperature

r o w * ’6

[9 W V

R

30

-6269

3694

0.59

2 0

40

-5082

-3119

0.61

19(a)

50

-2354

-1668

0.71

14(a)

60

-3147

-1902

0.60

15(a)

% Helicity
(a)

-2871
-1814
70
0.63
15(a)
“Units for [0] are deg cm2 dmol'1.
T b e minimum for the [0]*-** band is observed in the range from - 205-209 nm.
‘The minimum for the [0]»-«* band is observed in the range from - 222-225 nm.
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Table 3.9 CD data and derived structural parameters for Ipidab-9 in buffer (pH = 7) at
30 to 70 °C.

Temperature

[0 ]*-**

[8 W W

R

% Helicity

30

-1143

-8 6 8

0.76

12

(a)

40

-156

-189

1 .2

10

(a)

50

-626

-608

0.97

11

(a)

60

-549

-500

0.91

11

(a)

11

(a)

-664
70
-487
0.73
j
_2
j
.-1
“Units for [0] are deg cm2 dmol'1.
*The minimum for the [0]*-** band is observed in the range from ~ 205-209 nm.
T h e minimum for the [0]x-nt* band is observed in the range from ~ 222-225 nm.

The greatest percentage of a-helicity for each peptide was shown at 30 °C. As the
temperature increased to 70 °C, the general trend observed was weakening of the helicity
of the peptides, which was indicated graphically by the decreasing intensity of the molar
eilipticities of the characteristic minima and numerically by the calculated, decreasing
percent helicity (Figure 3.18, Figure 3.19, Figure 3.20, Figure 3.21).

Interestingly,

Ipidap-9, which didn’t have a well-defined structure in buffer at 25 °C, possessed the two
minima transition bands characterized by helical peptides at 30-70 °C. In this study, no
helix-coil transition nor a-helix to 3io-helix transition was observed. Furthermore, data
obtained by heating and cooling experiments for each peptide were not significantly
different, which demonstrate the reversibility of the thermal transition from 30 to 70 °C
in buffer.3"55
There appeared to have been a small a- to 3to-helical transition in 25 mM SDS for
Ipi-9 in the temperature range of 30 to 70 °C (Table 3.11 and Figure 3.22). This is based
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Table 3.10 CD data and derived structural parameters for Ipidap-9 in buffer (pH = 7) at
30 to 70 °C.

Temperature

[0 W *

[9 W * C

R

% Helicity

30

-6100

-3793

0.62

20(a)

40

-6375

-3585

0.56

20(a)

50

-3258

-2193

0.67

16(a)

60

-3736

-2106

0.56

15(a)

70

-4348

-2525

0.58

17(a)

“Units for [0] are deg cm2 dmol'1.
^The minimum for the [0]*_«« band is observed in the range from - 205-209 nm.
“The minimum for the [©]*_*** band is observed in the range from ~ 222-225 nm.
on the percent 3io-helicity and R values of Ipi-9. At 30 °C and 70 °C the R values and
percent 3io-helicity of Ipi-9 are 0.5, 13% and 0.38, 18%, respectively. For Ipiom-9, the
percent 3to-helidty (~9%) remains fairly constant over the range of temperatures in 25
mM SDS; however, there was a noticeable decrease in the R values (Table 3.11 and
Figure 3.23).

At 30 °C and 70 °C the R values of Ipiom-9 were 0.42 and 0.26,

respectively. Overall, it appears that both Ipi-9 and Ipiom-9 possess their designed 310helical structures in 25 mM SDS at higher temperatures (30 to 70 °C).
Increasing the temperature of a SDS micelle solution generally increases its
critical micelle concentration (CMC).336 Our studies were performed in 25 mM SDS,
which is high above its CMC; therefore, the concentration of micelles versus monomer
surfactants may not have changed significantly with the increase in temperature.
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Figure 3.18 CD spectra o f Ipi-9 at 30°C (e),40°C (----- -), 50°C (------ ),
60°C (------ ), 70°C-(------ ) in neutral, aqueous buffer.
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Figure 3.19 CD spectra o f Ipiom-9 at 30°C ( e),40°C (■), 50°C (♦), 60°C (▼),
and 70°C (+) in neutral, aqueous buffer.
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Figure 3JO CD spectra of Ipidab-9 at 30°C (
),40°C (------ ), 50°C (------ ),
60°C (------ ), 70°C (------ ) in neutral, aqueous buffer.
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Figure 3.21 CD spectra of Ipidap-9 at 30°C (
),40°C (-------), 50°C (---60°C (------ ), 70°C-(------ ) in neutral, aqueous buffer.
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However, the size and shape of the micelles could have possibly changed during the rise
in temperature. Ramesh and Labes337 suggest a spherical to cylindrical to a bilayer
structure as the temperature increases. It has been suggested that the differences in
helical content are possibly due to the relative binding affinity of peptides with SDS
micelles.319 Increasing the temperature of our SDS solution may have modified the
shape or size of the micelles resulting in a more favorable interaction with the peptides.
Table 3.11 CD data and derived structural parameters for Ipi-9 in 25 mM SDS at
30 to 70 °C.
Temperature

[0 W ^

30

-2727

R

% Helicity

-1380

0.50

13 (3,0)

•

40

-3277

-1548

0.47

15 (3I0)

50

-3258

-1349

0.41

15(3,o)

60

-3731

-1385

0.37

17(3,o)

-3813
-1467
0.38
18 (3, o)
2
j
i-l
“Units for [0] are deg cm2 dmol*1.
*The minimum for the [0]*-** band is observed in the range from ~ 205-209 nm.
‘The minimum for the
band is observed in the range from ~ 222-225 nm.
70

A study was also conducted on the effect of the different solvent systems
described above on the designed 3io-helical acetylated peptides 3.S-3.9. Blocking of the
N-terminus, as well as the C-terminus, of a designed helical peptide generally adds to its
stability; it eliminates the fixed-end charges that could cause either destabilization of
helices or inhibition of formation of helices.338 Stability is also afforded helical peptides
that are N-acetylated at the N-terminus due to the additional hydrogen bond; the carbonyl
of the blocking group acts an extra hydrogen bond acceptor.3'16 The first reported
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Table 3.12 CD data and derived structural parameters for Ipiom-9 in 25 mM SDS at
30 to 70 °C.

Temperature

[0 ]n-*x*a’C

R

%Helicity

30

-1941

-812

0.42

9(3,o)

40

-1860

-695

0.37

9 (3,0))

50

-1893

-735

0.38

9(3,o)

60

-1958

-435

0 .2 2

9(3,o)

-1944
70
-515
0.26
9(3,0)
“Units for [0] are deg cm2 dmol*1.
*The minimum for the [0]*-«* band is observed in the range from ~ 205-209 nm.
“The minimum for the [0]*-** band is observed in the range from ~ 222-225 nm.
experimental CD spectrum for a right-handed 3,o-helical peptide in TFE was a short,
hydrophobic, acetylated peptide (Ac-[L-(a-Me)Val]8-OtBu) . 3' 1 Also, the acetylated
peptide, Ac-Aib-ATANP-(Aib)2-ATANP-(Aib)2 -OMe, was the first reported example of
a short peptide assuming 3io-helical conformation in pure water.3 1 6

Peptide 3.6

(AcIpiom-9) assumed its designed 3io-helical structure appreciably in 25 mM SDS and
CH3CN-TFE (9:1). Its R values and percent 3io-helicity was, in SDS, 0.42 and 11%,
respectively, and 0.24 and 20%, respectively, in CH3CN-TFE (9:1) (Table 3.13; Figure
3.24; Figure 3.25). Peptide 3.7 (AcIpidab-9) assumed a 3to helical structure in CH3CNTFE (9:1) with a R value of 0.49 and 22% estimated 3io-helicity (Table 3.14), and
peptide 3.10 assumed a 310-helical structure in 25 mM SDS with a R value of 0.38 and 41
% 3io-helicity (Table 3.15). For the other acetylated peptides, 3.5 (Table 3.16) and 3.8
(Table 3.17), mainly a-helices formed in the six solvent systems, particularly in neutral
buffer (Figure 3.26) and CH3CN-H2O (9:1) (Figure 3.27), employed except for 3.8 in 25
mM SDS, in which no clear helical or secondary structure was evident.
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Table 3.13 CD data and derived structural parameters for AcIpiom-9 at 25 °C.

[B L /

[0 W ftf

R

%Helicity

25 mM SDS

-2432

-1037

0.42

11 (3 to)

9:1 CH3CN-TFE

-4287

-1023

0.24

20 (3 to)

9:1 CH3CN-H2 O

-11606

-11811

1

45(a)

3:1 CH3CN-H2 O

-3510

-3044

0.85

18(a)

1:1 CH3CN-H2 O

-2489

-2003

0.80

15(a)

Buffer (pH = 7)

-7330

-8145

1 .1

34(a)

Solvent

“Units for [0] are deg cm2 dmol'1.
*The minimum for the [0]x-*k« band is observed in the range from ~ 205-209 nm.
'The minimum for the [0]*-** band is observed in the range from ~ 222-225 nm.

Table 3.14 CD data and derived structural parameters for AcIpidab-9 at 25 °C.

Solvent

[0 W w

R

%Helicity

25 mM SDS

-1706

-983

0.57

9:1 CH3CN-TFE

-4700

-2329

0.49

22(3,o)

9:1 CH3CN-H2O

-1513

-2660

1.7

17(a)

3:1 CH3CN-H2O

-1600

-1433

0.89

13(a)

1:1 CH3CN-H2O

-1303

-1654

1 .2

14(a)

1 2

(a)

Buffer (pH = 7)
16(a)
-2228
-2451
1 .1
“Units for [0] are deg cm2 dmol*1.
^The minimum for the [0],_«* band is observed in the range from - 205-209 nm.
The minimum for the [0]*_*» band is observed in the range from - 222-225 nm
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Table 3.15 CD data and derived structural parameters for Aclpi-10 at 25 °C.
[0 ] « V 4

te w * "

R

% Helicity

25 mM SDS

-8814

-3362

0.38

41 (310)

9:1 CH3CN-TFE

-25375

-19938

0.78

70(a)

9:1 CH3CN-H2O

-12701

-13864

1.1

51(a)

3:1 CH3CN-H2O

-12240

-12714

I

47(a)

1:1 CH3CN-H2O

-9857

-10075

1

40(a)

Solvent

-9794
-9294
0.94
Buffer (pH = 7)
37(a)
“Units for [0] are deg cm2 dmol'1.
T h e minimum for the
band is observed in the range from ~ 205-209 nm.
T h e minimum for the [0]*-** band is observed in the range from - 222-225 nm.

Table 3.16 CD data and derived structural parameters for AcIpi-9 at 25 °C.
Solvent

t e w 1’*

R

% Helicity

25 mM SDS

-4877

-3151

0.64

d

9:1 CH3CN-TFE

-19472

-13295

0.68

49(a)

9:1 CH3CN-H2O

-18611

-17432

0.93

62(a)

3:1 CH3CN-H2O

-9548

-8136

0.85

34(a)

1:1 CH3CN-H2O

-8025

-7748

0.96

32(a)

-4277
Buffer (pH = 7)
-3998
1.1
22(a)
“Units for [0] are deg cm2 dmol'1.
T he minimum for the [0]*_** band is observed in the range from ~ 205-209 nm.
The minimum for the [0]*-»** band is observed in the range from ~ 222-225 nm.
T he % a-helix is estimated at 19%, and the % 3to-heIix is estimated at 23%.
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Figure 3.24 CD spectra o f AcIpi-9 (•), AcIpiom-9 (■), AcIpidab-9 (▼) and Aclpidap9 (4) in 25 mM SDS.
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Figure 3.25 CD spectra of AcIpi-9 (•), AcIpiom-9 (■), AcIpidab-9 (▼) and Aclpidap9 (♦) in CH3CN-TFE (9:1) at 25°C.
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Figure 3.26 CD spectra of AcIpi-9 (■), AcIpiom-9 (•), AcIpidab-9 (♦) and Aclpidap9 (▼) in buffer.
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Table 3.17 CD data and derived structural parameters for AcIpidap-9 at 25 °C.

Solvent

[ 0 U 4i

te w * '

R

%Helicity

9:1 CH3CN-TFE

-1898

-1618

0.85

14(a)

9:1 CH3CN-H20

-5963

-7554

1 .2

32(a)

3:1 CH3CN-H2O

-4017

-3188

0.79

19(a)

1:1 CH3CN-H2O

-6008

-4980

0.82

24(a)

Buffer (pH = 7)

-5895

-6515

0.9

29(a)

“Units for [0] are deg cm2 dmol*1.
*The minimum for the [0]*-»x*band is observed in the range from ~ 205-209 nm.
cThe minimum for the [0]*-»x«band is observed in the range from ~ 222-225 nm.
The helicity of AcIpi-9 and AcIpiom-9 was measured in buffer at three different
pH’s, 2,4, and 7 (Table 3.18 and Table 3.19). Based on the R values (0.87-1.1) of both
peptides, a-helicity is predominantly observed at all tested pH’s. The most stable ahelical structure was observed for AcIpiom-9 at pH 4. For both acetylated peptides the
weakest a-helical structure was observed at pH 2 (Figure 3.28 and Figure 3.29). The
more acidic medium may have interfered with the helices’ intramolecular hydrogen
bonding pattern.
In our study, we observed an average increase in stability (based on general
increase in ellipticity) with the acetylated peptides vs. the non-acetylated peptides. Also,
our actual design (3io-helical) of the peptides were observed best with the acetylated
peptides, specifically, AcIpiom-9, AcIpidab-9, and Aclpi-10 in either or both 25 mM
SDS and CH3CN-TFE (9:1) (Figure 3.12 and Figure 3.13). Particularly noteworthy are
the differences in CD data obtained for Ipiom-9 and its acetylated version, AcIpiom-9.
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The designed, 3to-helical structure of Ipiom-9 was observed best in buffer, where its R
value is 0.48. However, AcIpiom-9 was better stabilized (based on molar ellipticity) as
an a-helix in buffer, where its R value is 1.1. The R values of Ipiom-9 in 25 mM SDS (R
= 0.72) and in CH3CN-TFE (9:1, R = 0.66) indicate that Ipiom-9 exhibits more a-helical
than 3io-helical structures in these solvent systems. In contrast, the R values of Aclpiom9 in 25 mM SDS (R = 0.42) and in CH3CN-TFE (9:1, R = 0.24) indicate that AcIpiom-9
folded appreciably into its designed, 3 10-helical structure under these solvent conditions.
Table 3.18 CD data and derived structural parameters for AcIpi-9 at 25 °C.
PH

[ 0 W 4i

[e w ^

R

% Helicity

2

-1873

-1722

0.92

14(a)

4

-2619

-2474

1

17(a)

7

-3998

-4277

1 .1

2 2

(a)

“Units for [0] are deg cm2 dmol'1.
^The minimum for the [0]*-** band is observed in the range from 205-209 nm.
cThe minimum for the [0]*-*** band is observed in the range from 222-225 nm.

Table 3.19 CD data and derived structural parameters for AcIpiom-9 at 25 °C.
PH

[0 W *

[ 0 W ac

R

2

-4268

-3714

0.87

2 0

4

-12431

-11282

0.91

43(a)

7

-7330

-8145

1 .1

34(a)

% Helicity

“Units for [0] are deg cm2 dmol'1.
*The minimum for the [©]*-,*• band is observed in the range from ~ 205-209 nm.
cThe minimum for the [0]*_«* band is observed in the range from ~ 222-225 nm.
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Figure 3.28 CD spectra of AcIpi-9 in buffer at pH 7 ( •), pH 4 (■) and pH 2( t )
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Figure 3.29 CD spectra of AcIpiom-9 in buffer at pH 7 ( • ) , pH 4 (■) and pH 2 (r)
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The 3io-helical design of our peptides were in accord with the general factors
(e.g., helix length, number of Aib’s, position of a-amino acids) that favor 3io-helix
formation, although a-helices were observed for most of the peptides under the six
solvent conditions. The amphipathic design tool, undoubtedly, played a major role in the
3io-helices considerably forming in the above, acetylated peptides, especially in the SDS
micelle media. The length of the side-chains may have also been a factor, particularly for
AcIpiom-9. The shortening of AcIpi-9 to AcIpiom-9 led to R values, in 25 mM SDS and
CH3CN-TFE (9:1), that were more indicated of a 3io-helix. However, further shortening
of the side-chains of AcIpiom-9 to AcIpidab-9 and AcIpidap-9 led to R values that were
increasingly above the accepted value (R = < 0.4). Furthermore, the extra hydrogen bond
and slight increase in hydrophobicity in the acetylated peptides may have resulted in the
increased propensity of 3.6-3.7 to fold into a 3 10-helix in 100 % organic media.
3.2.3 Bioactivity of Designed Peptides
Many natural antimicrobial peptides of greatly differing sequences have been
isolated with amphipathic, helical domains as a consistent structural feature.3'20' 3'21 Also,
scores of de novo peptides that comprise only a putative amphipathic helix have activity
comparable to or greater than that of natural peptide antibiotics.330,3'22 As discussed in
the previous section, our peptides were designed to be amphipathic, like natural
antimicrobial peptide, as well as 3to-helical. Amphipathic peptides with 18 or more
residues could possess high cytotoxicity.339 It’s been reported that by simply reducing
the length of peptides to 14 residues decrease cytotoxicity while retaining much of the
antimicrobial activity.330,322 Peptides 3.1-3.8 were prepared to test the hypothesis that
retention of biological activity and lowering of cytotoxicity could be achieved by further
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shortening (main and side-chains) of the 10-mer peptide, Ipi-10. The secondary structure
of the peptides in the model membrane, SDS, was correlated with their biological
activity.
The MIC’s (minimum inhibitory concentration) for the peptides tested against
Escherichia coli and Staphylococcus aureus are summarized in Table 3.20. E. coli is a
Gram-negative bacterium, and S. aureus is a Gram-positive bacterium. The distinction
between Gram-negative and Gram-positive bacteria is based on the differential staining
procedure, Gram Stain. Gram-negative bacteria stains red, but Gram-positive, purple.
This difference in reaction to the Gram Stain is due primarily to the differences in the cell
wall structure of Gram-negative and Gram-positive bacteria. 3'40 The cell wall of a Gramnegative bacteria is multilayered; it is comprised of thin layer of peptidoglycan (layer
composed of N-acetylglucosamine, N-acetylmuramic acid, and a few amino acids) and an
outer membrane composed of lipopolysaccharaide, lipoprotein, and other complex
macromolecules. The cell wall of Gram-positive bacteria, on the other hand, consists
chiefly of a thick layer of peptidoglycan; it lacks the outer membrane present in Gramnegative cells.3 40
Peptide 3.1 (Ipi-9) inhibits the growth of E. coli at a minimum concentration of
140 pM; it is about 3 times less active than 3.2 (Ipiom-9). Ipidab-9 (33) inhibits E. Coli
at approximately 149 pM, which is comparable to 3.1. Ipidap-9 (3.4), with a MIC greater
than 300 pM, was the least active toward E. coli. Of the acetylated peptides 33-3.8,
AcIpi-9 (33), with a MIC of 134 pM, exhibited the best activity against E. coli. None of
the peptides had particularly good inhibitory activity against 5. aureus.
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Antimicrobial peptides kill bacteria by disrupting the cell membrane.3' 19' 3'20 It’s
been reported that the CD spectra of peptides in micelles suggest a structure/function
relationship for the bioactive peptides.3^ 0 SDS has an aliphatic tail and a negatively
charged head group (sulfate).

The micelles that SDS forms partially emulate the

amphipathic environment of membranes. The anionic head groups provide the initial
electrostatic interactions (with cationic side groups of peptides) needed and enhances the
binding affinity of peptides to the non-polar interior, thereby, inducing an intrinsic,
ordered structure. Because Ipi-9, of the four, non-acetylated designed peptides, possesses
the most amphipathic, 3io-helical structure in SDS, it was expected to be the most active
against the bacteria; however, Ipiom-9 was the most active. Ipiom-9 did, however, have
the highest, of the four peptides in all the tested six solvent systems, percentage of
amphipathic, 3io-helicity in buffer. The order of activity of Ipidab-9 and Ipidap-9, third
and fourth, respectively, was expected. Ipidab-9 had 19% amphipathic, 3io helicity in
buffer but very little estimated 3io helicity in SDS. Ipidap-9, on the other hand, lacked a
well-defined structure in all of the solvent systems tested except the

100%

organic

solvent system, CH3CN:TFE (9:1), in which a-helicity was mainly observed. Overall,
the shortening of Ipi-10 (MIC, 7.7 pM) to make 3.1-33 resulted in diminished, but
modest activity, against E. coli and no improvement in activity against S. aureus.
Aclpi-10 inhibits E. coli at approximately 7.4 pM; it also exhibited 41% 3io
helicity in SDS with a R value of 0.38. Shortening of Aclpi-10 to AcIpi-9 resulted in
reduced activity. However, of the designed acetylated peptides (33-3.8), activity against
E. coli was only observed for AcIpi-9 (33); it also had the highest estimated percent of
amphipathic, 3io helicity in 25 mM SDS. Practically no activity against 5. aureus was
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observed for any of the peptides. This may have been due in part to the much thicker cell
wall (peptidoglycan) S. aureus possesses compared to E. coli. Although E. coli has a
very thin peptidoglycan, it also has, as mentioned earlier, an additional outer membrane
not present in S. aureus. However, the outer membrane is relatively permeable to small
molecules.3'40
Overall, the shortening of the 10-mers, by removing the N-terminus, positively
charged residue (Api) resulted in reduced 3io-helicity as well as diminished antimicrobial
activity against E. coli. The larger polar face associated with the non-acetylated 10-mer
(Ipi-10), compared to the non-acetylated 9-mers, apparently has better peptide-membrane
interactions in SDS and E. coli. Seemingly, only small, if any, repulsive forces between
the charged Api residue and the N-terminal amine of the non-acetylated 10-mer exist. In
any case, elimination of the adjacent charges, by removing the N-terminus Api, doesn’t
apparently improve helicity or bioactivity. However, acetylation of the 10-mer does
improve 3io-helicity and bioactivity. Therefore, the larger polar face of the 10-mer
evidently overcomes any unfavorable like charge-charge effects.
The activity of our peptides against intracellular pathogens, like brucella, was not
tested; however, their degree of toxicity to normal murine macrophages was examined.
Macrophages are large white blood cells that ingest foreign particles and infectious
microorganism by phagocytosis. Table 3.21 shows normal murine macrophage survival
versus peptide concentration for the peptides 3.1*3.10. Cell death was indicated by the
enclosure of a trypan blue dye within a cell. Normal untreated murine macrophages have
a survival rate of ~ 90%.

No cytolytic effects were observed for Ipi-10; however,

shortening it to the 9-mer peptides didn’t lead to any significant cytotoxicity at
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concentrations < 100 pM.

Ipiom-9 wasn’t significantly toxic up to the maximum

concentration o f200 pM. However, 3.1 and 33-3.4 were slightly toxic at 200 pM. None
of the tested acetylated peptides, based on the presence of a very few to zero blue cells,
exhibited any significant cytotoxicity.
It is generally accepted that antimicrobial peptides selectively inhibit and kill
bacteria ova: mammalian cells due to differences in their membranes.3,20,3'41 The exterior
membranes of mammalian cells are neutral, but bacteria cell exterior membranes are
negatively charged. Because antimicrobial peptides are positively charged, they might
preferentially bind to bacteria over mammalian cells. In a previous study,'3-17 J-26 the
highest or optimum peptide dose, which was the maximum nontoxic to very slightly toxic
dose, that showed > 70% macrophage survival was used as the starting dosage to
determine if infected macrophages were selectively destroyed relative to non-infected
macrophages; the average dose used in this study was 10 pM for amphipathic peptides of
length 10-14 residues. For our 9-mer peptides, a starting dose as high as 200 pM could
possibly be employed without significant toxicity to the normal macrophages.
The acetylated peptides showed very little cytotoxicity compared to non-acetylated
peptides.

It’s desirable that this be translated into greater selectivity with good

bioactivity for the acetylated peptides. It has been reported in other similar systems that
short Aib-rich peptides (11-14 residues, acetylated and non-acetylated) kill infected
macrophages significantly better than non-infected macrophages in vitro?26 However,
the acetylated peptides tended to be less effective than its respective non-acetylated
versions at killing infected macrophages; this was especially observed, for these other
systems, in vivo. For this above study, the acetylated peptides generally had less than
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good activity against intracellular pathogens in vivo. iV-terminus acetylation decreases
the overall charge of a peptide while increasing the hydrophobidty, which may lessen the
amount of peptide actually making it to the infected macrophages present in the spleen
(in vrvo study). It was hoped that our water-soluble, acetylated and non-acetylated 9mers could overcome possible transport problems in vivo. Also, since our peptides are
not very significantly toxic at concentrations as high as 200 pM, it is hoped that this
Table 3.20 Peptide antibacterial activity0 and percent helicity
Peptide

E. Coli

S. aureus

% Helicity

3.1 Ipi-9

140

>281

23,* 16c

3.2 Ipiom-9

36

>290

6 ,*

3.3 Ipidab-9

149

>300

4,* 19c

3.4 Ipidap-9

>300

>300

d

3.5 AcIpi-9

134

>268

23*

3.6 AcIpiom-9

>277

>277

11*

3.7 AcIpidab-9

>285

>285

8*

3.8 AcIpidap-9

>295

>295

e

7.7

>247

25f

3.9 Ipi-10

24c

3.10 Aclpi-10
7.4
>237
41*
0 These MIC (in pM) are corrected for the actual peptide concentration using quantitative
amino acid analysis.
* % 3io-helicity in 25 mM SDS at 25 °C
c % 3io-helicity in buffer (pH = 7) at 25. °C
d Peptide 3.4 lacks well-defined structure in 25 mM SDS and neutral buffer.
*Peptide 3.8 lacks well-defined structure in 25 mM SDS.
f % 3io-helicity in 25 mM SDS at 5 °C; it’s only 5 % at 25 °C.
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correlates with great selectively of bacterial killing over normal mammalian cells, which
would have to be determined via in vivo and in vitro testings.
Table 3.21 Direct peptide toxicity effects on murine peritoneal macrophages
Peptide

200 pM

100 pM

50 pM

10 pM

3.1 Ipi-9

20 % Dead

95 % Viable

95 % Viable

95 % Viable

3.2 Ipiom-9

90 % Viable

90 % Viable

95 % Viable

95 % Viable

3.3 Ipidab-9

20 % Dead

No Effect

No Effect

No Effect

3.4 Ipidap-9

20 % Dead

95 % Viable

95 % Viable

95 % Viable

3.5 AcIpi-9

No Effect

No Effect

No Effect

No Effect

3.6 AcIpiom-9

Granular
Appearance
Very few blue
CeUs. 95 %
Viability

Beginning to
have granular
appearance. 95
% Viability

3.8 AcIpidap-9

Granular
appearance.
Very few blue
cells. 95 %
Viability

Beginning to
have granular
appearance.
95 % Viability

95 % Viability

95%
Viability

3.9 Ipi-10

Fewer cells but
no lytic effects

Fewer cells but
no lytic effects

Cells more
granular in
appearance

No Effect

No Effect

No Effect

No Effect

No Effect

3.10 Aclpi-10

Less granular
“Fried looking
cells present, but in appearance.
No blue ceils
no blue cells.
95 % Viability
present. 95100%
Viability
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33 Conclusions
Peptides 3.1-3.10, which are rich in aaAAs ( 6 Aibs and 1 Api), were successfully
prepared using solid-phase synthethic techniques. The in situ coupling reagent, PyAOP,
was employed in our synthesis. The overall yields of the peptides were significantly
improved when the dimer, Fmoc-Aib-Aib-OH, was used in the synthesis; however, the
monomer, Aib, had to be employed, along with double coupling, for the first two Aibs in
each peptide's sequence.
Peptides 3.1-3.8, whose main-chains were based on the previously described Ipi10 (3.9), were designed to be amphipathic, 3io-helical peptides. The solvents effects on
each peptide’s 3io-/a-helix equilibrium were measured in aqueous buffer, 25 mM SDS,
and 50-100 % aqueous/organic solvent mixtures. For the non-acetylated peptides 3.1-33,
significant populations of both a-and 3io-helices were observed in all of the solvent
systems tested. Ipidap-9, which was composed of the shortest a-amino acid side-chains,
was helical (mainly a-helix) only in the 90% organic solvent mixture. The amphipathic,
3 10-helical design was observed best, of peptides 3.1-3.4, for 3.2 (Ipiom-9, R = 0.48) in a
neutral, aqueous buffer at 25 °C. We found that Ipi-10, which is apparently 3io-helical (R
= 0.32, 25% helicity) at low temperatures (0-5 °C) in 25 mM SDS and 100% organic
solution (CH3CN-TFE, (9:1)), is more a-helical at 25 °C in these solvent systems as well
as under the other solvent conditions it was measured in. This wasn’t a trend or tendency
observed in the other peptides. However, the shortening of Ipi-10 to Ipi-9 did result in
better 3io-helical stabilization in 25 mM SDS at 25 °C.
Based on the absolute ellipticity values, a general decrease in stability was
observed for the peptides in buffer upon heating to 70 °C. We found that the thermal
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transition of each peptide was appreciably reversible. An isodichroic point was not
observed during the temperature or solvent studies, which indicates that these are not
simple two-state equilibria, but complex equilibria involving three or more folding
intermediates.
The 3 10-helical, amphipathic design, based on R values, was observed best for the
acetylated peptides, specifically 3.6 (Aclpiom) and 3.10 (Aclpi-10). Peptide 3.6 folded
appreciably into a 3io-helix in 25 mM SDS and CH3CN-TFE (9:1) and peptide 3.10, in 25
mM SDS. AcIpidab-9 also folded considerably into a 3io-helix in CH3CN-TFE (9:1). In
buffer, all of the acetylated peptides (R =1) folded mainly into an a-helix.
The antimicrobial activity of our designed peptides was tested against E. coli and
S. aureus. The shortening of Ipi-10 to 3.1-3.4 resulted in diminished but modest activity
against E. coli. Of the non-acetylated peptides 3.1-3.4, 3.2 (Ipiom-9), which had the
highest percent 3io-helicity in neutral buffer, had the best activity against E. coli. Aclpi9, which had the highest estimated 3to-helicity in 25 mM SDS, was the only acetylated
peptide of 3.S-3.8 to exhibit any activity against E. coli. Of all ten of the peptides, 3.10
(Aclpi-10), which displayed a R value of 0.38 and 41% 3io-helicity in SDS micelles, had
the best activity against E.coli. Practically no activity against S. aureus was observed for
any of the peptides.
The shortening of Ipi-10 to the 9-mer peptides did not lead to any significant
cytotoxicity in the concentration range of 10-100 uM. Peptides 3.1 and 3.3 were slightly
toxic at 200 uM.

None of the tested acetylated peptides exhibited any significant

cytotoxicity. This may bode well for the potential selectivity of these peptides for Iyses
of infected/activated macrophages over non-infected/non-activated macrophages.3' 18
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3.4 Experimental
3.4.1 Peptide Synthesis
Peptides 3.1-3.10 were synthesized via solid-phase peptide synthesis using a
Milligen 9050 peptide synthesizer on a PAL-PEG-PS (0.24 nunol/g) solid support. The
peptides were prepared on a 0.24 mmol scale using the Fmoc-amino acids (0.96 mmol, 4
equiv.), preformed Fmoc-Aib-Aib-OH (0.96 mmol, 4 equiv.), PyAOP (0.96 mmol, 4
equiv.), DIEA (1.92 mmol,

8

equiv.), 1.2 h recycling time, and a jacket temperature of

50 °C. The monomer, Fmoc-Aib-OH, was employed only in the coupling of the first two
Aibs in the peptide sequences. A double coupling was performed after each Fmoc-AibOH. A deblocking solution of 2% piperidine/2% l,8-diazobicyclo[4.5.0]undec-7-ene
(DBU) in DMF was used for Fmoc removal. Peptides 3.1-3.4 and 3.9 were acetylated on
the solid support (0.12 mmol) by treatment with a 0.2 M solution of acetic anhydride in a
0.28 M solution of DIEA in DMF for 3 hours.
The peptides were simultaneously cleaved from the resin and side-chain
deprotected using the following cleavage cocktail: 94% trifluoroacetic acid (TFA), 5%
water, and 1% triisopropylsilane (TIPS). The resulting acidic solution was diluted with
30% acetic acid and lyophilized. The crude peptides were purified by reverse-phase
preparative HPLC on a Waters 15 pM DeltaPak C-4 column using a mobile phase of
water (0.05%, v/v, TFA) and acetonitrile (0.05%, v/v, TFA) and running a gradient of
10% to 50% of the organic phase over 1 hour, the absorption was monitored at 222 nm.
Purities of the peptides were checked on a Vydac 5 pM Cig column running a similar
mobile phase gradient and monitoring at 222 nm. The molecular weight of each purified
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peptide was verified by matrix assisted laser desorption ionization (MALDI) mass
spectrometry (Table 3.22).
3.4.2 V-tert-Butyloxycarbonyl-4-[lV2-(9-fluoreiiylmetlioxycarbonyl)
amino]-piperidine-4-carboxyIic acid3'42
^^^-tris-tert-butyloxycarbonyl-S.lO-dioxo^J^-triazaspirotS^lcycIodecane
was prepared from piperidine-4-spiro-5'-hydantoin according to a procedure described in
reference 3.38.

To

a vigorously stirring suspension

of W W ^-tris-tert-

butyloxycarbonyl-8,10-dioxo-4,7,9-triaza-spiro[5,4]cyclodecane (33 g, 71 mmol) in THF
(300 ml,) was added 2 N KOH (300 mL). After stirring for 18 hours, the two-layer clear
solution was poured into a separatory funnel and then the aqueous layer was drained into
Table 3.22 Characterization of Peptides 3.1-3.10
Peptide

tR(min.)a

Calculated Mass

MALDI®

Ipi-9

2 2 .6

910.16

910.99 (M + H)+

Ipiom-9

21.9

882.11

883.67 (M + H)+

Ipidab-9

2 1 .8

854.06

854.25 (M)+

Ipidap-9

2 1 .6

826.01

849.24 (M + Na)+

AcIpi-9

29.4

952.21

953.21 (M + H)+

AcIpiom-9

29.1

924.15

925.47 (M +H)+

AcIpidab-9

29.0

896.10

897.16 (M + H)+

AcIpidap-9

28.5

868.05

869.01 (M. + H)+

Ipi-10

26.2

1036.32

1037.38 (M + H f

1078.74 (M + H)+
1078.36
Aclpi-10
32.5
aReverse-phase HPLC carried out on a C4 column ( 8 x 100 mm) using a mobile phase of
H2O (0.05% TFA) and CH3CN (0.05% TFA), gradient of 10 to 50% organic phase over
lh, and a flow rate of 1 mL/min.
*CCA matrix (CH3CN-H20).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

129

a round bottom flask. Residual THF was removed by rotary evaporation. The aqueous
layer was acidified to pH 7 with 2 N HC1. The resultant white precipitate was filtered
and dried in vacuo to yield l-tert-butyloxycarbonyl-4-amino-piperidine-4-carboxylic
acid. Yield: 15 g (8 8 %). ‘H NMR (250 MHz, CD3SOCD3) 8 1.42 (s, 9 H) 1.90 (m, 4 H),
3.58 (m, 4 H).
According to Bolin’s procedure, 333 under argon, anhydrous methylene chloride
(150 mL) and DIEA (9.14 mL, 52.4 mmol) was syringed into a flask containing 1-tertbutyIoxycarbonyl-4-amino-piperidine-4-carboxylic acid (5.12 g, 20.9 mmol). The
reaction mixture stirred for 15 minutes at room temperature.

Chlorotrimethylsilane

(TMS-C1) (5.32 g, 41.9 mmol) was then added dropwise , and the solution was heated to
reflux for 3 hours. After cooling in an ice bath, 9-fluorenylmethyl chloroformate (5.45 g,
21.1 mmol) was added in one portion. The solution was stirred in the ice bath for 20
minutes and for 3 hours at room temperature. The solvent was evaporated, and the
product was distributed between Et2 0 (70 mL) and 2.5% Na2CC>3 (300 mL). The
aqueous layer was separated and washed with additional portions of Et2 0 (2 x 30 mL).
Residual Et2 0 was removed from the aqueous layer by rotary evaporation and acidified
to pH 2 in an ice bath using 2 N HC1. The precipitated free acid was extracted with
EtOAc (100 mL) and additional portions of EtOAc (2 x 60 mL). The combined EtOAc
fractions were dried over MgSC>4 and filtered. The solvent was removed by rotary
evaporation, and the resulting yellow solid was dried in vacuo. Yield: 9 g (93%). *H
NMR (250 MHz, CD3OD) 8 1.40 (s, 9H), 1.75 (m, 2H), 1.96 (m, 2H), 3.04 (m, 2H), 3.76
(m, 2H), 4.37 (m, 3H), 7.25 (t, 2H), 7.30 (t, 2H), 7.70 (d, 2H), 7.90 (d, 2H). FABMS
(NBA) m/e 465.3 (M - H)\
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3.43 A-(9-FluorenylmethoxycarbonyI)aminoisobutyric acid fluoride [Fmoc-Aib-F]
Under argon, Fmoc-Aib-OH (10 g, 30 mmol) was suspended in CH2CI2 (100 mL)
followed by the addition of pyridine (2.4 mL, 30 mmol) and cyanuric fluoride (5.1 mL,
61 mmol). The reaction mixture stirred at room temperature for 24 hours, and then it was
diluted with CH2CI2 (150 mL), poured onto ice-water, and filtered. The organic layer
was extracted with ice water (2 x 200 mL), dried over MgS04, and evaporated in vacuo
to yield the acid fluoride as a pink solid. The product was recrystallized from the solvent
pair, CH2Cl2/hexane. Yield:

8

g (82%). ‘H NMR (250 MHz, CDCI3) 6 1.45 (s, 6 H), 4.25

(t, 1H), 4.46 (d, 2H), 7.42 (m, 5H), 7.78 (d, 2H), 7.95 (d, 2H).
3.4.4 Fmoc-Aib-Aib-OH
a-Aminoisobutyric acid (3.01 g, 29.2 mmol) was placed in a flask equipped with
a condenser, heating mantle, and an argon inlet.

Anhydrous CH2CI2 (70 mL) was

syringed into the reaction vessel followed by the addition of TMS-C1 (7.4 mL, 58.4
mmol). The mixture was refluxed for 2 hours and then cooled in an ice bath. DIEA
(9.17 mL, 52.6 mmol) and Fmoc-Aib-F (6.37 g, 19.4 mmol) were added in succession.
The reaction mixture was stirred with cooling for 20 minutes and then warmed to room
temperature for 2 hours. The solvent was evaporated, and the resulting residue was
distributed between Et2 0 (160 mL) and 2.5% NaHCC>3 (210 mL). The aqueous layer was
extracted with 2 x 50 mL of Et2 0 . The aqueous layer was then acidified to pH 2 with 1 N
HC1 and extracted with EtOAc (3 x 80 mL). The combined EtOAc fractions were then
dried over Na2S0 4, filtered, concentrated, and dried in vacuo. The final product was
recrystallized from the solvent pair, CHCls/hexane. Yield: 5.5 g (70%). *H NMR (250
MHz, CD3SOCD3)

8

1.33 (s, 12H), 4.25 (t, 1H), 4.4 (d, 2H), 7.32 (m, 4H), 7.56 (d, 2H),
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7.83 (d, 2H), 12.24 (bs, 1H). MALDI (CCA) 411.34 (M + H)+. Analysis calculated for
C23H26N2 0 5 : C, 67.32; H, 6.34; N, 6.83; Found: C, 67.51; H, 6.39; N, 6.77.
3.4.5 Amino A dd Analysis
The concentrations of the Peptides (3.2-3.10) were determined by quantitative
amino acid analysis. Peptide samples containing a norleucine standard were hydrolyzed
in

6

N HCI and 0.1% phenol for 24 h at 110 °C. This was followed by sodium cation

exchange chromatography at 65 °C and post-column derivatization with ninhydrin at
130 °C. The peptide contents of lyophilized powders were between 67% and 80%
peptide by weight.
3.4.6 Circular Dichroism Measurements
Circular dichroism measurements were performed on a (+)-camphor sulfonic acid
calibrated Aviv 60DS spectropolarimeter at room temperature (except where noted). The
measurements were recorded over a 250-180 range using a quartz cell of 0.1 cm path
length, 1 nm bandwidth, 10 nm/min scan speed, and a 5 second time constant. Baseline
corrections were performed by subtracting each sample spectrum from its respective,
acquired background spectrum. Three repetitive scans were recorded and averaged to
improve the signal to noise ratio. Ellipticity is reported as the mean residue ellipticity [6 ]
>

in units of deg cm2 dm'1, and it’s derived from the formula, [0] = [0]obs (MRW/10/c),
where

[0]obs is the ellipticity measured in millidegrees, MRW is the mean residue

molecular weight of the peptide (molecular weight divided by the number of peptide
bonds), c is the concentration (mg/mL) of the sample, and I is the optical path length (cm)
of the cell.
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CD spectra of all peptides in this study were acquired in solvent systems ranging
from 100% organic to 100% aqueous (0% organic). Final peptide concentrations of 0.2
mM were used for the experiments. The peptides were dissolved in acetonitrile for
spectra taken in 9:1 CHbCNrTFE and 10 mM phosphate buffer (pH 7) for spectra taken in
SDS. The 10 mM phosphate buffer (pH 7) was also used as the aqueous component in
the aqueous/organic experiments (CH3CN/H2O).
3.4.7 Minimum Inhibitory Concentration Assays
The MIC of peptides was determined against E. Coli American type culture
collection (ATCC) 25922 and S. aureus ATCC 25723; they were employed as
representative Gram-positive and Gram-negative bacteria, respectively.

Bacterial

cultures were grown to midlog phase in nutrient broth and were standardized to a
McFarland turbidity tube before dilution. Peptide 1:2 serial dilutions were prepared from
512 pg/mL stock solutions to provide a range of peptide concentrations (256-2 pg/mL) in
the culture media. 50 pL of the desired peptide solution was added to a sterile well
containing 50 pL of 5 x 104 cells. The MIC is the lowest peptide concentration that
prevents the growth of the cells as evidenced by the absence of turbidty after four hours.
The MIC values are reported as the median assay value for at least three experiments.
3.4.8 Macrophage Assays
The peritoneal macrophages of the ten-week old BALB/c mice had to be extracted
before toxicity studies with peptides. Briefly, following euthanasia using halothane, the
cells were harvested by lavage from the peritoneal cavity of the mice using

8

mL of

RPMI 1640 (Sigma) + 10% fetal calf serum (FCS) and Pen-Strep (Penicillin and
Streptomycin). The cells were cultured in 96 well plates at a concentration of 5 x 10s
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cells per well in 200 fiL of RPM I1640 + 10% FCS at 37 °C in 5% CO2 . The cells were
allowed to adhere overnight.

The cell cultures were enriched for macrophages by

washing away non-adherent cells, and then

200

pL of fresh media was added to the

cultures.
For the toxicity studies, normal macrophage cultures were treated with 0 to 200
jiM of the test peptide. The peptides were incubated with the cells for 60 minutes at 37
°C in 5% CO2 . The cells were washed 3 times with PBS (phosphate buffered saline) +
10% FCS to remove any residual peptide. Peptide treated cells were stained with 0.04%
trypan blue in RPMI 1640 + 10% FCS and Pen-Strep. About 100 to 200 cells per well
were counted using a hemocytometer and an inverted light microscope. Five wells were
analyzed per peptide concentration; the number of blue stained cells was recorded. The
enclosure of trypan blue dye within a cell is indicative of cell death. The percent survival
was calculated by subtracting the number of blue cell from the total cells and normalized.
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Chapter 4
Summary and Future Studies
This dissertation focused on the synthesis and characterization of compounds
from two classes of peptide analogs, phosphonopeptides and a,a-dialkylated amino acidrich peptides. Compounds in both classes of analogs have been reported to exhibit
significant bioactivity. The P (El) synthetic approach to phosphonopeptides provided a
route to phosphonamide dipeptides la and lc (Figure 4.1) which were previously
unattainable by P (V) methods.

Additionally, the use of reduced phosphorus

intermediates allowed preparation of the related thiophosphamides lb and Id (Figure
4.1). Ten a,a-dialkylated amino acid (aaAA)-rich peptides, which were designed to be
amphipathic and 3io-helical, were successfully prepared using solid-phase synthetic
methods. The helix preference of each peptide in different solvent environments were
investigated as well as each peptide’s antimicrobial activity and cytotoxicity.

la
lb
lc
Id

X = 0 ,Y = NH2
X = S, Y = NH2
X = O, Y = OCH3
X = S, Y = OCH3

Figure 4.1 Main phosphonamide and thiophosphonamide synthetic targets
Phosphonamides are generally more difficult to prepare than phosphonate
diesters. Phosphonamidate’s poor synthetic accessibility has severely limited the use of
this interesting class of compounds as tools in enzyme chemistry. Chapter 2 described
136
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the

conditions

we

developed,

based

on

a

one-pot

activation-coupling-

oxidation/sulfurization procedure, for preparation of sterically hindered phosphonamide
and thiophosphonamide dipeptides. The commercially available PhsPCfe was used for
activation of our air-stable precursor, Cbz-protected H-phosphinate amino acid ester
[Cbz-CyhGly \jr(POH (OpNb)]. From a GC-MS study, it was determined that the
presence of two equivalents of base (pyridine) during activation of the H-phosphinate
amino acid ester with PI13PCI2 was essential to preclude ester cleavage. However, as the
number of equivalents of base increased from two to large excess (e.g., pyridine as
solvent), the number and amount of side-products increased, as evident by 31P NMR.
The optimized activation step was generally high-yielding.
During the coupling step, a reactive phosphitylating agent, which we proposed to
be an oxazaphospholine, formed and competed with the formation of the desired,
intermediate phosphonamidites. Since the proposed oxazaphospholine was very reactive
(electrophilic), it was purposely generated before the amine-coupling step. Each aminenucleophile was coupled to the oxazaphospholine, instead of the initial activated P (III)
species (a phosphonochioridite), to form two coupling, diastereomeric products instead of
the possible four. This may have indicated a lack of stereoselectivity when amine adds
directly to the phosphonochioridite.
Oxidation and sulfurization of the intermediate phosphonamidites were easily
accomplished with t-butylhydroperoxide and elemental sulfur, respectively. Using our
developed conditions, the previously inaccessible phosphonamide hapten precursor la
and related derivatives lb-d were prepared. In an alternate procedure, we found that the
addition of 2 equivalents of an amine-nucleophile with 3.5 equivalents of DEEA to the
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phosphonochioridite followed by sulfiirization/oxidation could also form 1 , but as a
mixture of four diastereomers instead of two. The former method, incorporating the
oxazaphospholine, was also applied in the preparation of simpler phosphonamide and
thiophosphonamide dipeptides and thiophosphonates.
The potential use of the non-urethane amine-protecting groups, Dde and Nbs,
were also investigated in our phosphonopeptide syntheses.

These amine-protecting

groups were incorporated to lessen the formation of cyclized intermediates or
oxazaphospholines, which is sometimes undesired in peptide synthesis. The coupling of
an amine-nucleophiie to a Nbs-protected phosphonochioridite results in the expectant
diastereomeric mixture of phosphonamidites along with only a small amount of the
proposed oxazaphospholine. However, with a Dde-protected phosphonochioridite, the
formation of an oxazaphospholine isn’t observed during amine-coupling, but the overall
coupling reaction with this type of species doesn’t proceed as well as the reaction with a
Nbs-protected phosphonochioridite.
Future studies in the area of phosphonopeptide synthesis using reduced
phosphorus species include the incorporation of non-participating amino protection (via
solution-or solid-phase), use of milder activation agents, development of analytical
conditions or techniques for separation of diastereomeric mixtures of phosphonopeptides,
and solid-supported approaches. The amenability of the P (III) synthetic approach to
solid-phase methods could be very valuable. In phosphonopeptides prepared by the P
(IQ) protocol, diversity can be achieved around the phosphorus center as well as by the
different side-chains of the a-amino acids coupled to them. Therefore, the next logical
step, for the long-term, would be the adaptation of the solid-phase methodology to the
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simultaneous synthesis (combinatorial chemistry) of several peptides, which could be
beneficial in the search for therapeutic agents.
Chapter 4 described the synthesis of short, aaAA-rich peptides, the effects of
different solvent environments on their 3to-/a-helix equilibrium, and the peptides’ in vitro
antimicrobial activity and cytotoxicity. The peptides were designed to be amphipathic
and 3io-helical. They were prepared to test the hypothesis that shortened, amphipathic
3 10-helical peptides would retain biological activity while becoming increasingly
selective Cess cytotoxic) in bacterial killing over normal mammalian cells. This was
based on the trend observed between the length of a peptide and cytotoxicity and helicity
and bioactivity. The trend was that the shorter the peptide the higher and lower the
selectivity and cytotoxcity, respectively, and the more helical the peptide the greater the
activity.
Four homologous series of 9-mer, actAA-rich peptides (and their acetylated
versions) as well as previously described 10-mer peptide (and its acetylated version) were
successfully prepared using solid-phase synthetic methods. The 9-mers were comprised
of 78% aaAAs (6 Aibs and 1 Api) and two lysine or lysine-like residues, and the 10-mers
were composed of 80% aaAAs (6 Aibs and 2 Api’s) and two lysines. The 9-mers
differed only in the length of their a-amino acid side-chains. The in situ coupling agent,
PyAOP, was used in the synthesis. The coupling yields as well as the overall yields of
the peptides were significantly improved when the dimer, Fmoc-Aib-Aib-OH, was
employed in the synthesis; however, it was essential that the monomer, Aib, be
incorporated, along with double coupling, for the first two Aibs in each peptide’s
sequence.
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The solvent effects on each peptide’s 3 io-/a-helix equilibrium were measured in
aqueous buffer, 25 mM SDS, and 50-100% aqueous/organic solvent mixtures.
Significant populations of both a- and 3io-helices were generally observed for the nonacetylated 9-mer peptides under all of the solvent conditions tested. Ipidap-9, which was
comprised of the shortest a-amino acid side-chains, was helical (mainly a-helix) only in
CH3CN:H2 0 (9:1). The amphipathic, 3io-helical design was observed best, of the nonacetylated 9-mers, for Ipiom-9 (R = 0.48) in neutral, aqueous buffer at 25 °C.
Interestingly, Ipi-10, which is apparently 3io-helical (R = 0.32) at 5 °C in SDS micelles
and CH3CN-TFE (9:1), is more a-helical at 25 °C under these solvent conditions as well
as in the other solvent environments it was measured in. This wasn’t a trend observed in
the other peptides. Further shortening of Ipi-10 to Ipi-9, however, did result in the better
3 10-helical stabilization in 25 mM SDS at 25 °C.
A temperature study was also conducted on the 9-mer peptides.

A general

decrease in stability, based on absolute ellipticity values, was observed for the peptides in
buffer upon heating to 70 °C. However, the thermal transition of each peptide was
appreciably reversible. Furthermore, during the temperature studies as well as the solvent
studies no isodichroic point was observed.
The 3io-helical, amphipathic design, based on R values, was observed best for the
acetylated peptides, specifically AcIpiom-9 and Aclpi-10. AcIpiom-9 folded appreciably
into a 3io-heIix in 25 mM SDS and CH3CN-TFE (9:1) and Aclpi-10, in 25 mM SDS.
AcIpidab-9 also adopted the 3io-helical conformation to a substantial extent in CH3CNTFE (9:1). In buffer, all of the acetylated peptides (R=l) folded mainly into an a-helix.
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The antimicrobial activity of our designed peptides was tested against E. coli and
S. aureus. The shortening of Ipi-10 to the 9-mer peptides resulted in diminished but
modest activity against E. coli. Of the non-acetylated peptides, Ipiom-9, which had the
highest percent 3io-helicity in neutral buffer, had the best activity against E. coli. Aclpi9, which had the highest estimated 3io-helicity in 25 mM SDS, was the only acetylated
peptide of the acetylated-9-mers to exhibit any activity against E. coli. Of all ten of the
peptides, Aclpi-10, which displayed a R value of 0.38 and 41% 3jo-helicity in SDS
micelles, had the best activity against E.coli. Practically no activity against S. aureus was
observed for any of the peptides.
The shortening of Ipi-10 to the 9-mer peptides did not lead to any significant
cytotoxicity in the concentration range of 10-100 uM. Ipi-9 and Ipidab-9 were only
slightly toxic at 200 uM. None of the tested acetylated peptides exhibited any significant
cytotoxicity.
Potential future studies include the introduction of a suitable transition metal or
salt bridges for possible induction of helical stabilization (preferably 3io-heIix) in the 9mer, aaAA-rich peptides and the determination of the effects (e.g., helix preference and
stability, bioactivity, etc.) of increasing the length of the side-chains of the 9-mers
(starting from Ipi-9). The in vitro and in vivo testing of the 9-mers (acetylated and nonacetylated) against intracellular pathogens, like Brucella, is also a potential future area of
investigation.
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